

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau

(43) International Publication Date  
7 August 2003 (07.08.2003)

PCT

(10) International Publication Number  
WO 03/063874 A1(51) International Patent Classification<sup>7</sup>: A61K 31/519,  
31/502, 31/4725, C07D 239/88, 495/04, 471/04, 491/04,  
401/06, 237/32, 217/24, A61K 31/517 // (C07D 495/04,  
335:00, 239:00) (C07D 471/04, 239:00, 221:00) (C07D  
491/04, 311:00, 239:00)

(21) International Application Number: PCT/JP03/00708

(22) International Filing Date: 27 January 2003 (27.01.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
PS 0197 29 January 2002 (29.01.2002) AU

(71) Applicant (for all designated States except US): FUJISAWA PHARMACEUTICAL CO., LTD. [JP/JP]; 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ISHIDA, Janya




[JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). HATTORI, Kouji [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). KUDO, Yoshiyuki [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP). YAMAMOTO, Hirofumi [JP/JP]; c/o Fujisawa Pharmaceutical Co., Ltd., 4-7, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka 541-8514 (JP).

(74) Agent: TABUSHI, Eiji; c/o Fujisawa Pharmaceutical Co., Ltd., Osaka Factory, 1-6, Kashima 2-chome, Yodogawa-ku, Osaka-shi, Osaka 532-8514 (JP).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: CONDENSED HETEROCYCLIC COMPOUNDS



(57) Abstract: A condensed heterocyclic compound having poly(adenosine 5'-diphospho-ribose)polymerase (PARP) inhibitory activity represented by the formula (I): wherein R<sup>1</sup> is hydrogen, halogen, lower alkyl or lower alkoxy, A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, etc., -Y<sup>1</sup>=Y<sup>2</sup> is formula (II) wherein L<sup>11</sup>, L<sup>12</sup>, L<sup>13</sup> and L<sup>14</sup> is (1) lower alkylene, (2) lower alkenylene, etc., and R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup> and R<sup>24</sup> is (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s), etc., provided that when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, then -Y<sup>1</sup>=Y<sup>2</sup> is formula (III) or its tautomer or their salt.

**WO 03/063874 A1**

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/063874

PCT/JP03/00708

## DESCRIPTION

## Condensed Heterocyclic Compounds

## 5 Technical Field

This invention relates to novel condensed heterocyclic compounds having pharmacological activity, to a process for their production and to a pharmaceutical composition containing the same.

## 10 Background Art

Poly (adenosine 5'-diphospho-ribose) polymerase ["poly (ADP-ribose) polymerase" or "PARP", which is also sometimes called "PARS" for "poly (ADP-ribose) synthetase"] is an enzyme located in the nuclei of cells of various organs, including muscle, heart and brain cells. PARP plays a physiological role in the repair of strand breaks in

## 15 DNA. Once activated by damaged DNA fragments, PARP catalyzes the attachment of up to 100 ADP-ribose units to a variety of nuclear proteins, including histones and PARP itself.

Some condensed heterocyclic compound having inhibitory activity of PARP have been known, for example, in WO95/24379, WO98/33802 and WO99/11624.

20

## Disclosure of the Invention

This invention relates to novel condensed heterocyclic compound, which have pharmaceutical activity such as PARP inhibiting activity, to a process for their production, to a pharmaceutical composition containing the same and to a use thereof.

## 25 One object of this invention is to provide the novel condensed heterocyclic compound, which have a PARP inhibiting activity.

Another object of this invention is to provide a process for production of the condensed heterocyclic compound.

## 30 A further object of this invention is to provide a pharmaceutical composition containing the condensed heterocyclic compound as an active ingredient.

Still further object of this invention is to provide a use of the condensed heterocyclic compound for manufacturing a medicament for treating or preventing various diseases, or a method of treating or preventing various diseases by administering the condensed heterocyclic compound in an effective amount to inhibit PARP activity.


35

Thus, the present invention provides the following.

WO 03/063874

PCT/JP03/00708

[1] A compound of the formula (I):



wherein

5  $R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

10  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---N=C---} \\ | \\ L^{11} \\ | \\ R^{21} \end{array}$ ,  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

- 15 (1) lower alkylene,  
 (2) lower alkenylene,  
 (3) cyclo(lower)alkylene,  
 (4) cyclo(lower)alkenylene,  
 (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one  
 20 hydrogen atom from said monocyclic group, or  
 (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

- 25 (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,  
 30 (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally

WO 03/063874

PCT/JP03/00708

substituted with lower alkyl, or

(3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],


provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

then  $-Y^1=Y^2-$  is  $\text{---C=N---}$ ,  $\text{---CH=C---}$  or  $\text{---C=CH---}$ ,  
 $\text{L}^{12}\text{---R}^{22}$   $\text{L}^{13}\text{---R}^{23}$   $\text{L}^{14}\text{---R}^{24}$

or its prodrug, or their salts.

[2] The compound according to [1], wherein



[wherein  $X^1$  and  $X^2$  is N, O or S].

[3] The compound according to [2], wherein

$R^1$  is hydrogen, and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is tetrahydropyridyl, piperidyl or piperazinyl, each of which is substituted with aryl optionally substituted with halogen.


[4] The compound according to any one of [1], [2] and [3], wherein

L is lower alkylene.

[5] The compound according to any one of [1], [2], [3] and [4], wherein

$-Y^1=Y^2-$  is  $\text{---N=C---}$ ,  
 $\text{L}^{11}\text{---R}^{21}$

[6] A pharmaceutically composition comprising a compound of the formula (I):




WO 03/063874

PCT/JP03/00708

wherein

$R^1$  is halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,



[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

- (1) lower alkylene,
- (2) lower alkenylene,
- (3) cyclo(lower)alkylene,
- (4) cyclo(lower)alkenylene,
- (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or
- (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

- (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,
- (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or
- (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],


WO 03/063874

PCT/JP03/00708

provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded

with A form benzene ring,



5

or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity.


[7] The pharmaceutical composition of [6] for treating or preventing diseases ascribed by NMDA- and NO-induced toxicity.

[8] The pharmaceutical composition of [6] for extending the lifespan or proliferative capacity of cells or altering gene expression of senescent cells

[9] The pharmaceutical composition of [6] for treating or preventing tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Parkinson's disease; epilepsy; Amyotrophic Lateral Sclerosis (ALS); Huntington's disease; schizophrenia; chronic pain; ischemia and loss following hypoxia; hypoglycemia; ischemia; trauma; nervous insult; previously ischemic heart or skeletal muscle tissue; radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy; skin aging; arteriosclerosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; other immune senescence diseases; inflammatory bowel disorders (e.g., colitis); arthritis; diabetes; endotoxic shock; septic shock; or tumor.

[10] A method of inhibiting PARP activity comprising administering a compound of the formula:

30




wherein

WO 03/063874

PCT/JP03/00708

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,



[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

- (1) lower alkylene,
- (2) lower alkenylene,
- (3) cyclo(lower)alkylene,
- (4) cyclo(lower)alkenylene,
- (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or
- (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

- (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,
- (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or
- (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],

provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded




WO 03/063874

PCT/JP03/00708

with A form benzene ring,  
 then  $-Y^1=Y^2-$  is  $\text{---}\underset{\substack{| \\ L^{12} \\ | \\ R^{22}}}{C}=N\text{---}$ ,  $\text{---}CH=C\text{---}$  or  $\text{---}\underset{\substack{| \\ L^{14} \\ | \\ R^{24}}}{C}=CH\text{---}$ ,  
 or its prodrug, or their salts.

5 [11] A use of a compound of the formula (I):



wherein

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

10 A and two adjacent carbon atoms of the six membered ring to be bonded with A  
 form benzene ring, pyridine ring, or five to seven membered partially  
 saturated ring optionally containing one or more heteroatom(s) selected from  
 the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

15  $-Y^1=Y^2-$  is  $\text{---}N=\underset{\substack{| \\ L^{11} \\ | \\ R^{21}}}{C}\text{---}$ ,  $\text{---}\underset{\substack{| \\ L^{12} \\ | \\ R^{22}}}{C}=N\text{---}$ ,  $\text{---}CH=C\text{---}$  or  $\text{---}\underset{\substack{| \\ L^{14} \\ | \\ R^{24}}}{C}=CH\text{---}$ ,

[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

- (1) lower alkylene,
- (2) lower alkenylene,
- 20 (3) cyclo(lower)alkylene,
- (4) cyclo(lower)alkenylene,
- (5) diradical of saturated- or unsaturated monocyclic group with one  
 or more nitrogen atom(s), which is obtained after removal of one  
 hydrogen atom from said monocyclic group, or
- 25 (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is  
 lower alkylene or lower alkenylene), and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

- (1) cyclic amino group, which is substituted with phenyl optionally  
 substituted with one or more suitable substituent(s) selected from the  
 30 group consisting of halogen, nitro, lower alkoxy, lower alkyl,  
 halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally  
 substituted with lower alkyl,

WO 03/063874

PCT/JP03/00708

(2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or

(3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl],


provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

then  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

or its prodrug, or their pharmaceutically acceptable salts, for manufacturing a medicament for inhibiting PARP activity.

The condensed heterocyclic compound of this invention can be represented by the following formula (I):



wherein

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

$-Y^1=Y^2-$  is  $\begin{array}{c} \text{---N=C---} \\ | \\ L^{11} \\ | \\ R^{21} \end{array}$ ,  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

WO 03/063874

PCT/JP03/00708

- (1) lower alkylene,  
 (2) lower alkenylene,  
 (3) cyclo(lower)alkylene,  
 (4) cyclo(lower)alkenylene,  
 5 (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or  
 (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and  $L$  is lower alkylene or lower alkenylene), and  
 10  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is  
 (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally  
 15 substituted with lower alkyl,  
 (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally  
 20 substituted with lower alkyl, or  
 (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally  
 25 substituted with lower alkyl.],

provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

30 then  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ \text{---R}^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ \text{---R}^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ \text{---R}^{24} \end{array}$ ,


or its prodrug, or their salts.

The compound (I) or its prodrug, or their salt can be prepared by the following processes. In the following formulae, compounds may be prodrugs or their salts.

35

WO 03/063874

PCT/JP03/00708


Process 1

[wherein,  $\text{R}^1$ ,  $\text{R}^{21}$  and A are each as defined above, and  $\text{R}^3$  is lower alkyl.]

In this process, the compound (I-a) or its salts can be produced by reacting the  
 10 compound (II) or its salt and compound (III) in the presence of base, such as inorganic  
 bases, for example, an alkali metal [e.g., sodium or potassium], alkoxide, hydroxide,  
 carbonate or bicarbonate thereof, or organic bases such as a trialkylamine [e.g.,  
 trimethylamine or triethylamine] or the like.

The reaction is usually carried out in a conventional solvent such as an alcohol  
 15 (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane,  
 diethylether), amide (e.g., N, N-dimethylformamide, N, N-dimethylacetamide), nitrile (e.g.,  
 acetonitrile), or any other organic solvent which does not adversely affect the reaction.  
 The reaction may be usually carried out under cooling to heating since the reaction  
 temperature is not critical.

20

Process 2

[wherein,  $\text{R}^1$  and A are each as defined above, and  $\text{X}^3$  is CH or N,  $\text{L}^{15}$  has a same meaning  
 of  $\text{L}^{11}$  or  $\text{L}^{13}$ , and  $\text{R}^{25}$  has a same meaning of  $\text{R}^{21}$  or  $\text{R}^{23}$ .]

In this process, the compound (I-b) can be produced by subjecting the compound  
 30 (IV) to cyclization reaction in the presence of base, such as inorganic bases, for example,  
 an alkali metal [e.g., sodium or potassium], alkoxide, hydroxide, carbonate or bicarbonate  
 thereof, or organic bases such as a trialkylamine [e.g., trimethylamine or triethylamine] or  
 the like.


35 The reaction is usually carried out in a conventional solvent such as water, an  
 alcohol (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane,

WO 03/063874

PCT/JP03/00708

diethylether), amide (e.g., N, N-dimethylformamide, N, N-dimethylacetamide), nitrile (e.g., acetonitrile), or any other organic solvent which does not adversely affect the reaction. The reaction may be usually carried out under cooling to heating since the reaction temperature is not critical.

5

Process 3

[wherein, R¹ and A are each as defined above, and X⁴ is CH or N, L¹⁵ has a same meaning of L¹¹ or L¹³, Z is halogen, and

15


—N(R³)(R⁴) is substituted cyclic amino groups or optionally substituted amino group.]

In this process, the compound (I-c) or its salts can be produced by reacting the compound (IV) or its salt and compound (V) in the presence of base, such as inorganic bases, for example, an alkali metal [e.g., sodium or potassium], alkoxide, hydroxide, carbonate or bicarbonate thereof, or organic bases such as a trialkylamine [e.g., trimethylamine or triethylamine] or the like.

The reaction is usually carried out in a conventional solvent such as an alcohol (e.g., methanol, ethanol or isopropyl alcohol), ether (e.g., tetrahydrofuran, dioxane, diethylether), amide (e.g., N, N-dimethylformamide, N, N-dimethylacetamide), nitrile (e.g., acetonitrile), or any other organic solvent which does not adversely affect the reaction. The reaction may be usually carried out under cooling to heating since the reaction temperature is not critical.

WO 03/063874

PCT/JP03/00708

Process 4

10 [wherein, R¹ and A are each as defined above, and X⁵ is CH or N, L¹⁶ has a same meaning of L¹² or L¹⁴, Z is halogen, and

—N(R³)(R⁴) is substituted cyclic amino groups or optionally substituted amino group.]

This reaction can be carried out in the same manner as Process 3.

15

The compound of the present invention can be purified by any conventional purification methods employed for purifying organic compounds, such as recrystallization, column chromatography, thin-layer chromatography, high-performance liquid chromatography and the like. The compounds can be identified by conventional methods  
20 such as NMR spectrography, mass spectrography, IR spectrography, elemental analysis, and measurement of melting point.

Some of the starting compounds (II), (III), (IV) and (V) are novel and can be prepared by the well-known processes or its analogous processes, for example, the  
25 processes described in the WO2000/42025 and the processes shown in Preparations mentioned below.

Suitable salts of the compounds of the present invention are pharmaceutically acceptable conventional non-toxic salts and can be an organic acid addition salt (e.g.  
30 formate, acetate, trifluoroacetate, maleate, tartrate, oxalate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.), an inorganic acid addition salt (e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.), a salt with an amino acid (e.g. aspartic acid salt, glutamic acid salt, etc.), or the like.

The "prodrug" means the derivatives of compounds of the present invention  
35 having a chemically or metabolically degradable group, which becomes pharmaceutically active after biotransformation.

WO 03/063874

PCT/JP03/00708

The compounds of formula (I) may contain one or more asymmetric centers and thus they can exist as enantiomers or diastereoisomers. Furthermore certain compounds of formula (I) which contain alkenyl groups may exist as cis- or trans-isomers. In each instance, the invention includes both mixtures and separate individual isomers.

5 The compounds of the formula (I) may also exist in tautomeric forms and the invention includes both mixtures and separate individual tautomers.

The compound of the formula (I) and its salt can be in a form of a solvate, which is included within the scope of the present invention. The solvate preferably include a hydrate and an ethanolate.

10 Also included in the scope of invention are radiolabelled derivatives of compounds of formula (I) which are suitable for biological studies.

In the above and subsequent description of the present specification, suitable examples and illustrations of the various definitions, which the present invention includes  
15 within the scope thereof, are explained in detail as follows.

The term "lower" means a group having 1 to 6 carbon atom(s), unless otherwise provided.

Suitable "lower alkyl" includes a straight or branched alkyl having 1 to 6, in particular 1 to 2, carbon atoms. Preferable examples which may be mentioned are methyl,  
20 ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl and hexyl.

Suitable "lower alkoxy" includes straight or branched alkoxy having 1 to 6, in particular 1 to 2, carbon atoms. Preferable examples which may be mentioned are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, iso-butoxy, sec-butoxy and tert-butoxy, preferably methoxy. Suitable "lower alkylamino" include mono (lower) alkylamino and di  
25 (lower) alkylamino. Preferable examples which may be mentioned are methylamino, dimethylamino, ethylamino, dimethylamino, n-propylamino, isopropylamino, n-butylamino, iso-butylamino, sec-butylamino and tert-butylamino, preferably dimethylamino and diethylamino.

Suitable "lower alkylene" includes a straight or branched alkylene having 1 to 6,  
30 in particular 3, carbon atoms. Preferable examples which may be mentioned are methylene, ethylene, trimethylene, propylene, methyltrimethylene (1- or 2-methyltrimethylene) and hexamethylene, preferably trimethylene.

Suitable "lower alkenylene" includes a straight or branched alkenylene having 1 to 6, in particular 3, carbon atoms. Preferable examples which may be mentioned are  
35 vinylene, propenylene, dimethylpropenylene (e.g., 3,3-dimethylpropenylene, etc.) and hexenylene preferably propenylene.

WO 03/063874

PCT/JP03/00708

The term "halogen" means fluoro, chloro, bromo or iodo.

Suitable "halo(lower)alkyl" contains 1 to 4, in particular 1 or 2, carbon atoms, and preferably 1 to 9, in particular 1 to 5, identical or different halogen atoms, preferably fluorine, chlorine and bromine, in particular fluorine and chlorine. Examples which may be mentioned are trifluoromethyl, trichloromethyl, chlorodifluoromethyl, dichlorofluoromethyl, chloromethyl, bromomethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl, preferably trifluoromethyl.

Suitable "halo(lower)alkoxy" contains 1 to 4, in particular 1 or 2, carbon atoms, and preferably 1 to 9, in particular 1 to 5, identical or different halogen atoms, preferably fluorine, chlorine and bromine, in particular fluorine and chlorine. Examples which may be mentioned are trifluoromethoxy, trichloromethoxy, chlorodifluoromethoxy, dichlorofluoromethoxy, chloromethoxy, bromomethoxy, 1-fluoroethoxy, 2-fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2,2,2-trichloroethoxy and pentafluoroethoxy, preferably trifluoromethoxy.

The term carbocyclic group intended to mean cyclo(lower)alkyl or cyclo(lower)alkenyl.

Suitable "cyclo(lower)alkyl" and cyclo(lower)alkyl moiety in the term "cyclo(lower)alkylene" includes a saturated carbocycle having 3 to 7, in particular 5 to 6, carbon atoms. Preferable examples which may be mentioned are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl, preferably cyclopropyl and cyclohexyl.

Preferable example which may be mentioned as "cyclo(lower)alkylene" are cyclohexylene (e.g., 1,3- cyclohexylene, 1,4-cyclohexylene, etc.). Suitable "cyclo(lower)alkenyl" and cyclo(lower)alkenyl moiety in the term "cyclo(lower)alkenylene" includes a partially saturated carbocycle having 3 to 7, in particular 5 to 6, carbon atoms. Preferable examples which may be mentioned are cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl and cycloheptenyl, preferably cyclopentenyl and cyclohexenyl.

Preferable example which may be mentioned as "cyclo(lower)alkylene" are cyclopentenylene (e.g., 1,3-cyclocyclopent-1-enylene, etc.), cyclohexenylene (e.g., 1,3-cyclohex-1-enylene, etc.).

Suitable "heteroaryl" and heteroaryl moiety in the terms "heteroaryl(lower)alkyl" and "heteroaromatic acyl" is intended to mean 5- to 7-membered rings having preferably 1 to 3, in particular 1 or 2, identical or different heteroatoms. Heteroatoms in the heteroaryl are oxygen, sulfur or nitrogen. Examples which may be mentioned are furyl, thienyl, pyrazolyl, imidazolyl, triazolyl (e.g., 1,2,3- and 1,2,4-triazolyl, etc.), isoxazolyl, thiazolyl,



WO 03/063874

PCT/JP03/00708

isothiazolyl, oxadiazolyl (e.g., 1,3,4-, and 1,2,5-oxadiazolyl, etc.), azepinyl, pyrrolyl, pyridyl, piperazinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl (e.g., 1,3,5-, 1,2,4- and 1,2,3-triazinyl, etc.), oxazinyl (e.g., 1,2,4- and 1,2,6-oxazinyl, etc.), oxepinyl, thiocpinyl, diazepinyl (e.g., 1,2,4-diazepinyl, etc.), preferably thienyl, pyrazolyl, imidazolyl, thiazolyl, 5 pyridyl, pyrazinyl.

Suitable "cyclic amino group" are heteroaromatic or aliphatic ring systems having one or more nitrogen atoms as the heteroatom, in which the heterocyclic rings can be saturated or unsaturated, can be one ring system or several fused ring systems, and optionally contain further heteroatoms, such as nitrogen, oxygen and sulfur and the like.

10 Cyclic amino groups can furthermore also denote a spiro ring or a bridged ring system. The number of atoms which form cyclic amino groups is not limited, for example in the case of a single-ring system, they comprise 3 to 8 atoms, and in the case of a three-ring system, they comprise 7 to 11 atoms.

Preferable examples of "cyclic amino group" are described as follows:

15 (1) examples which may be mentioned of cyclic amino group with saturated monocyclic groups with one or more nitrogen atom(s) as the heteroatom are azetidiny (3-azetidiny), pyrrolidinyl (e.g., 1- and 3-pyrrolidinyl, etc.), piperidyl (e.g., piperidine, 4-piperidyl, etc.), homopiperidino (e.g., hexahydro-1H-azepin-1-yl, etc.), homopiperazinyl (e.g., hexahydro-1H-1, 4-diazepin-1-yl, etc.), imidazolidinyl (e.g., 1-imidazolidinyl, etc.), 20 piperazinyl (e.g., 1-piperazinyl, etc.), perhydropyrimidinyl (e.g., perhydropyrimidin-1-yl, etc.) or diazacycloheptanyl (e.g., 1,4-diazacycloheptan-1-yl, etc.);

(2) examples which may be mentioned of cyclic amino group with unsaturated monocyclic groups with one or more nitrogen atom(s) as the heteroatom are pyrrolinyl (e.g., 2-pyrrolin-1-yl, etc.), pyrrolyl (e.g., 1-pyrrolyl, etc), tetrahydropyridyl (e.g., 25 3,6-dihydro- ((2H)-pyridyl, etc.), pyridyl (e.g., 2-pyridyl, etc.), tetrahydroazepinyl (e.g., 2,3,6,7-tetrahydro-1H-azepin-1-yl, 2,3,4,7-tetrahydro-1H-azepin-1-yl, etc.), imidazolyl (1-imidazolyl), pyrazolyl, triazolyl, tetrazolyl, tetrazolyl, pyrimidinyl, pyrazinyl, pyridazinyl, dihydro-pyridazinyl (e.g., 1,2-dihydro-pyridazin-1-yl, etc.) or dihydro-pyrimidinyl (e.g., 1,2-dihydro-pyrimidin-1-yl, etc.);

30 (3) examples which may be mentioned of cyclic amino groups with saturated or unsaturated monocyclic groups with one to three nitrogen atoms and one to two sulfur atoms as heteroatoms are thiazolidinyl (e.g., 3-thiazolidinyl, etc.), isothiazolinyl (e.g., 2-isothiazolinyl, etc.) or thiomorpholino;

(4) examples which may be mentioned of cyclic amino groups with saturated or 35 unsaturated monocyclic groups with one to three nitrogen atoms and one to two oxygen atoms as heteroatoms are oxazolyl, isoxazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl, or

WO 03/063874

PCT/JP03/00708

1,3,4-oxadiazolyl) or morpholinyl;

(5) examples which may be mentioned of cyclic amino groups with saturated or unsaturated fused cyclic groups are indolyl (e.g., 1-indolyl, etc.), dihydrobenzimidazolyl (e.g., 1,2-dihydrobenzimidazol-1-yl, etc.), perhydropyrrolo[1,2-a]pyrazinyl (e.g.,

- 5 perhydropyrrolo[1,2-a]pyrazin-2-yl, etc.), tetrahydrobenzo[f]isoquinolinyl (e.g., 1,4,5,6-tetrahydrobenzo[f]isoquinolin-3(2H)-yl, etc.), hexahydrobenz[f]isoquinolinyl (e.g., cis- and trans-1,4,4a,5,6,10b-hexahydrobenz[f]isoquinolin-3(2H)-yl, etc.), tetrahydropyrido[3,4-b]indolyl (e.g., 1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl, etc.) tetrahydrobenzazepinyl (e.g., 1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl, etc.), or
- 10 dihydroisoquinolinyl (e.g., 3,4-dihydro-2(1H)-isoquinolinyl, etc.);

(6) examples which may be mentioned of cyclic amino groups with spirocyclic groups are azaspiro[4,5]decanyl (e.g., 2-azaspiro[4,5]decan-2-yl, etc.), spiro[1H-indene-1,4'-piperidyl] (e.g., spiro[1H-indene-1,4'-piperidin-1'-yl], etc.), or dihydrospiro[1H-indene-1,4'-piperidyl] (e.g.,

- 15 2,3-dihydrospiro[1H-indene-1,4'-piperidin-1'-yl], etc.);

(7) examples which may be mentioned of cyclic amino groups bridged heterocyclic groups are azabicyclo[2,2,1]heptanyl (e.g., 2-azabicyclo[2,2,1]heptan-7-yl, etc.), or diazabicyclo[2.2.1]heptyl (e.g., 2,5-diazabicyclo[2.2.1]hept-2-yl, etc.).

Among the above, preferable "cyclic amino group" included in R<sup>1</sup> is

- 20 above-mentioned (1) or (2), in which the most preferable one is piperidyl, tetrahydropyridyl or piperazinyl.

- Preferable examples which may be mentioned of "diradical of saturated or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group" are azetidinylene (e.g., 1,2- or
- 25 1,3-azetidinylene), pyrrolidinylene (e.g., 1,2- or 1,3- pyrrolidinylene), or piperidinylene (e.g., 1,3- or 1,4-piperidinylene).

- It has been known that, during major cellular stresses, the activation of PARP can rapidly lead to cell damage or death through depletion of energy stores and PARP
- 30 activation play a key role in both NMDA- and NO-induced neurotoxicity (Zhang et. al., Science, 263: 687-89 (1994)). Therefore, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in treating and preventing various diseases ascribed by NMDA- and NO-induced toxicity. Such diseases include, for example, tissue damage resulting from cell damage or
- 35 death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases;

WO 03/063874

PCT/JP03/00708

neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Parkinson's disease; epilepsy; Amyotrophic lateral Sclerosis (ALS); Huntington's disease; schizophrenia; chronic pain; ischemia and neuronal loss following hypoxia; hypoglycemia; ischemia; trauma; or nervous insult.

5 It has been demonstrated that PARP inhibitor are useful in deducing infarct size (Thiemermann et al, Proc. Natl. Acad. Sci. USA, 94: 679-83 (1997)). Therefore, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in treatment and prevention of previously ischemic heart or skeleton muscle tissue.

10 It is also known that PARP is thought to play a role in enhancing DNA repair. So, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy.

15 Further, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are useful in extending the life-span and proliferative capacity of cells and altering gene expression of senescent cells. They are useful for treating and preventing skin aging, Alzheimer's diseases; arteriosclerosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of  
20 skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; and other immune senescence diseases.

Still further, the compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing inflammatory bowel disorders (e.g., colitis); arthritis; diabetes;  
25 endotoxic shock; septic shock; or tumor. Also, they are useful in reducing proliferation of tumor cells and making synergistic effect when tumor cells are co-treated with an alkylating drug.

The compound possessing PARP inhibiting activity, such as the compound (I) of this invention, or pharmaceutically acceptable salts are effective in treating and preventing  
30 pituitary apoplexy; conjunctivitis; retinoblastoma; retinopathy; acute retinal necrosis syndrome; Sjogren's syndrome.

The compound (I), its prodrug, or their salt can be administered alone or in the form of a mixture, preferably, with a pharmaceutical vehicle or carrier.

The active ingredient of this invention can be used in the form of a pharmaceutical  
35 preparation, for example, in solid, semisolid or liquid form, which contains a compound (I), as an active ingredient, in admixture with an organic or inorganic carrier or excipient

WO 03/063874

PCT/JP03/00708

suitable for external (topical), enteral, intravenous, intramuscular, parenteral or intramucous applications. The active ingredient can be formulated, for example, with the conventional non-toxic, pharmaceutically acceptable carriers for ointment, cream, plaster, tablets, pellets, capsules, suppositories, solution (saline, for example), emulsion, suspension (olive oil, for example), aerosols, pills, powders, syrups, injections, troches, cataplasms, aromatic waters, lotions, buccal tablets, sublingual tablets, nasal drops and any other form suitable for use. The carriers which can be used are water, wax, glucose, lactose, gum acacia, gelatin, mannitol, starch paster, magnesium trisilicate, talc, corn starch, keratin, paraffin, colloidal silica, potato starch, urea and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form, and in addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used. The active compound is included in a pharmaceutical composition in an effective amount sufficient to produce the desired effect upon the process or condition of the diseases.

The active ingredient can be formulated into, for example, preparations for oral application, preparations for injection, preparations for external application, preparations for inhalation, preparations for application to mucous membranes.

Mammals which may be treated by the present invention include livestock mammals such as cows, horses, etc., domestic animals such as dogs, cats, rats, etc. and humans, preferably humans.

While the dosage of therapeutically effective amount of the compound (I) will vary depending upon the age and condition of each individual patient, an average single dose to a human patient of about 0.01 mg, 0.1 mg, 1 mg, 10 mg, 50 mg, 100 mg, 250 mg, 500 mg, and 1000 mg of the compound (I) may be effective for treating the above-mentioned diseases. In general, amounts between 0.01 mg/body and about 1,000 mg/body may be administered per day.

In order to illustrate the usefulness of the object compound (I), the pharmacological test data of the compound (I) are shown in the following.

#### A. Test Compound

- (1) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone  
(Compound A: The compound of Example 1)
- (2) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
(Compound B: The compound of Example 3-(10))
- (3) 4-[4-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)butyl]-1(2H)-phthalazinone

WO 03/063874

PCT/JP03/00708

(Compound C: The compound of Example 7)

(4) 4-[4-(9-Methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)butyl]-  
1(2H)-phthalazinone

(Compound D: The compound of Example 9-(7))

5

**B. PARP inhibitory activity (In vitro assay)****(1) Assay conditions:**

The recombinant human PARP (5.3mg protein/ml) were incubated with a test compound in a 100μl reaction buffer containing the indicated concentration of 1 mCi/ml <sup>32</sup>P-NAD, 50mM Tris-HCl, 25mM MgCl<sub>2</sub>, 1mM DTT (dithiothreitol), 0.05mM NAD (nicotinamido adenine dinucleotide), 1mg/ml activated DNA, pH8.0. Incubation was for 15 minutes at a room temperature and the reaction was stopped by the addition of 200μl of ice-cold 20% trichloroacetic acid followed by rapid filtration through GF/B filters. The filters were treated with scintillation fluid and acid-insoluble counts were measured for quantification of unit activity.

PARP inhibitory activity (%) =

[1-(enzyme activity with test compound)/(enzyme activity with vehicle)] x100

**(2) Result****20 PARP inhibitory activity (IC<sub>50</sub>) in test compound.**

Test Compound	IC <sub>50</sub> (μM)
Compound A	< 0.5
Compound B	< 0.5
Compound C	< 0.5
Compound D	< 0.5

This invention relates to novel Quinazolinone compounds had a potent PARP inhibitory activity. PARP inhibitors including this invention relates to novel quinazolinone compounds were effective in preventing reduction of striatal DA and its metabolite induced by MPTP treatment in mice. Therefore, it suggests that these compounds may have protective benefit in the treatment of neurodegenerative disease such as Parkinson's disease.

Abbreviations used herein have the following meanings:

ABBREVIATION	DEFINITION
Me	methyl
Et	ethyl

WO 03/063874

PCT/JP03/00708

	TBu	tert-buthyl
	Bzl	benzyl
	Ph	phenyl
	Ac	acetyl
5	Bz	benzoyl

Any patents, patent applications, and publications cited herein are incorporated by reference.

#### Best Mode for Carrying out the Invention

- 10 The following Preparation and Examples are given for the purpose of illustrating the present invention in detail, but are not to be construed to limit the scope of the present invention.

##### Preparation 1

- 15 To a solution of 3,4-difluorobromobenzene (5.81 g) in tetrahydrofuran (50 ml) was added dropwise n-butyl lithium (19.3 ml) at - 78 °C under nitrogen. The mixture was stirred at the temperature for 0.5 hour. To the mixture was added dropwise a solution of t-Butyl 4-oxo-1-piperidinecarboxylate (5 g) in tetrahydrofuran (20 ml) at - 78 °C, and the mixture was stirred for 1 hour, then warmed to 0 °C and stirred for further 1 hour.
- 20 The reaction was quenched with water and extracted with ethyl acetate twice. The combined extracts were dried over magnesium sulfate and concentrated. This crude t-Butyl 4-(3,4-difluorophenyl)-4-hydroxy-1-piperidinecarboxylate was used for the next step without further purification.

##### 25 Preparation 2

- To a solution of t-butyl 4-(3,4-difluorophenyl)-4-hydroxy-1-piperidinecarboxylate (8.96 g; net: 7.79 g) in dichloromethane (98 ml) were added in sequence methanesulfonylchloride (5.77 ml), triethylamine (34.7 ml) and 4-dimethylaminopyridine (152 mg). After stirring at room temperature for 2 hours, the mixture was diluted with
- 30 water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. A solution of the residue and triethylamine (34.7 ml) in dichloromethane (98 ml) was stirred at room temperature for 2 days. The mixture was diluted with water and the organic layer was separated. The organic extract was dried over magnesium sulfate and concentrated. The residue was chromatographed on
- 35 silica gel using 10% ethyl acetate in hexane as an eluent to give t-Butyl 4-(3,4-difluorophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate (4.37 g) as an oil.

WO 03/063874

PCT/JP03/00708

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.50 (9H, s), 2.40 - 2.60 (2H, m), 3.63 (2H, t,  $J=5.7$  Hz),  
3.90 - 4.20 (2H, m), 5.97 (1H, s), 6.80 - 7.40 (4H, m).

Mass (ESI): 318.2 ( $\text{M}+\text{Na}$ ) $^+$

### 5 Preparation 3

To a solution of t-butyl 4-(3,4-difluorophenyl)-3,6-dihydro-1(2H)-pyridinecarboxylate (4.3 g) in ethyl acetate (20 ml) was added dropwise 4N hydrogen chloride in ethyl acetate (18.25 ml), and the mixture was stirred at room temperature overnight. After evaporation of the mixture, the residue was triturated with ethyl acetate  
10 and diisopropylether, and the resulting powder was collected, washed with diisopropylether and dried in vacuo to give 4-(3,4-Difluorophenyl)-1,2,3,6-tetrahydropyridine hydrochloride (3.25 g).

$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 2.20 - 4.20 (6H, m), 6.09 (1H, s), 7.00 - 7.80 (3H, m),  
9.07 (2H, brs)

15 Mass (ESI): 196.2 ( $\text{M}+\text{H}$ ) $^+$

### Preparation 4

To a suspension of L-alanine methyl ester hydrochloride (12.9 g) and triethylamine (38.6 ml) in dichloromethane (130 ml) was added dropwise  
20 chloroacetylchloride (8.83 ml) at 0 °C. After stirring at 0 °C for 30 minutes, the mixture was concentrated and diluted with ethyl acetate (100 ml) and 1N aqueous hydrochloric acid (100 ml). The organic layer was separated, washed with water twice, dried over magnesium sulfate and concentrated. A solution of the residue in 40% ethyl acetate in hexane (200 ml) was treated with silica gel (85 g), and silica gel was removed by filtration  
25 and washed with 40% ethyl acetate in hexane (200 ml) twice, and the combined filtrate was concentrated to give methyl (2S)-2-[(chloroacetyl)amino]propanoate as a brown oil.

$^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 1.30 (3H, d,  $J=7.3$  Hz), 3.64 (3H, s), 4.09 (2H, s),  
4.20-4.35 (1H, m), 8.64 (1H, d,  $J=6.8$  Hz)

Mass (ESI): 202.2 ( $\text{M}+\text{Na}$ ) $^+$

30

### Preparation 5

A solution of methyl (2S)-2-[(chloroacetyl)amino]propanoate (5 g), 4-chloroaniline (3.55 g) and triethylamine (11.6 ml) in toluene (50 ml) was stirred at 100 °C overnight. The mixture was diluted with water (100 ml) and extracted with ethyl  
35 acetate twice. The combined extracts were washed with water and brine, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel

WO 03/063874

PCT/JP03/00708

using 50% ethyl acetate in hexane as an eluent to give methyl  
(2S)-2-({[(4-chlorophenyl)amino]acetyl}amino)propanoate (3.07 g) as an oil.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.27 (3H, d, J=7.3 Hz), 3.31 (3H, s), 3.66 (2H, d, J=6.0 Hz), 4.20 - 4.50 (1H, m), 6.12 (1H, t, J=6.0 Hz), 6.54 (2H, d, J=8.8 Hz), 7.1 (2H, d, J=8.8 Hz), 8.32 (1H, d, J=7.2 Hz).  
Mass (ESI): 293.2 (M+Na)<sup>+</sup>

#### Preparation 6

A slurry of methyl (2S)-2-({[(4-chlorophenyl)amino]acetyl}amino)propanoate (3.02 g) and potassium t-butoxide (2.5 g) in toluene was stirred at 80 °C overnight. After cooling to room temperature, the reaction was quenched with 1N aqueous hydrochloric acid and extracted with ethyl acetate twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using 80% ethyl acetate in hexane as an eluent to give (3S)-1-(4-Chlorophenyl)-3-methyl-2,5-piperazinedione (1.5 g).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.37 (3H, d, J=7.0 Hz), 4.11 (1H, q, J=7.0 Hz), 4.22 (1H, d, J=16.6 Hz), 4.32 (1H, d, J=16.6 Hz), 7.30 - 7.60 (4H, m), 8.41 (1H, brs)  
Mass (ESI): 261.1 (M+Na)<sup>+</sup>

#### 20 Preparation 7

The following compound was prepared in a similar manner to that of Preparation

4.

(1) Ethyl 2-((chloroacetyl)amino)-2-methylpropanoate

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.14 (3H, t, J=7.1 Hz), 1.36 (6H, s), 3.80 - 4.20 (4H, m), 8.52 (1H, brs)  
Mass (ESI): 230.2 (M+Na)<sup>+</sup>

#### Preparation 8

The following compound was prepared in a similar manner to that of Preparation

30 5.

(1) Ethyl 2-({[(4-chlorophenyl)amino]acetyl}amino)-2-methylpropanoate

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.10 (3H, t, J=7.1 Hz), 1.35 (6H, s), 3.61 (2H, d, J=6.0 Hz), 4.00 (2H, q, J=7.1 Hz), 6.54 (2H, d, J=8.8 Hz), 7.09 (2H, d, J=8.8 Hz), 8.17 (1H, brs)  
Mass (ESI): 321.2 (M+Na)<sup>+</sup>



WO 03/063874

PCT/JP03/00708

Preparation 9

The following compound was prepared in a similar manner to that of Preparation

6.

(1) 1-(4-Chlorophenyl)-3,3-dimethyl-2,5-piperazinedione

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.42 (6H, s), 4.32 (2H, s), 7.20 - 7.70 (4H, m), 8.50 (1H, brs)

Mass (ESI): 275.1 (M+Na)<sup>+</sup>

Preparation 10

To a suspension of lithium aluminum hydride (225 mg) in tetrahydrofuran (7.5 ml) was added in portions 1-(4-chlorophenyl)-3,3-dimethyl-2,5-piperazinedione (0.5 g), and the mixture was stirred at 50 °C for 3 hours. After cooling to room temperature, the reaction was quenched with 1N aqueous sodium hydroxide (0.5 ml). The resulting precipitates were removed by filtration and washed with ethyl acetate, and then the combined filtrate was washed with brine, dried over magnesium sulfate and concentrated. A solution of the residue in ethyl acetate was treated with 4N hydrogen chloride in ethyl acetate (1 ml), and the mixture was concentrated. The residual oil was triturated with a small amount of acetone, and then the resulting powder was collected, washed with acetone and dried in vacuo to give 1-(4-Chlorophenyl)-3,3-dimethylpiperazine hydrochloride (0.22 g).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.37 (6H, s), 3.00 - 3.40 (6H, m), 7.02 (2H, d, J=9.0 Hz), 7.28 (2H, d, J=9.0 Hz), 9.08 (2H, brs)

Mass (ESI): 225.3 (M+H)<sup>+</sup>

25 Preparation 11

The following compound was prepared in a similar manner to that of Preparation

10.

(1) (3S)-1-(4-Chlorophenyl)-3-methylpiperazine hydrochloride

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.29 (3H, d, J=6.5 Hz), 1.80 - 4.30 (7H, m), 6.90 - 7.40 (4H, m)

Mass (ESI): 211.2 (M+H)<sup>+</sup>

Preparation 12

A mixture of 4-bromochlorobenzene (2 g), 2-amino-2-methyl-1-(triphenylmethyl)aminopropane (4.83 g), tris(dibenzylideneacetone)dipalladium (287 mg), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (390 mg), sodium t-butoxide (1.4 g) in toluene

WO 03/063874

PCT/JP03/00708

(24 ml) was stirred at 120 °C under nitrogen for 2 hours. After cooling to room temperature, the mixture was diluted with diisopropylether and filtered, and the filtrate was concentrated. The residue was chromatographed on silica gel using 10% ethyl acetate in hexane as an eluent to give 2-(4-chlorophenyl)amino-2-methyl-1-(triphenylmethyl)amino-

5 propane (2.83 g).

<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.30 (6H, s), 1.92 (1H, t, J=6.8 Hz), 2.27 (1H, d, J=6.8 Hz), 3.59 (1H, brs), 6.26 (2H, d, J=8.8 Hz), 6.91 (2H, d, J=8.8 Hz), 7.10 - 7.70 (15H, m)

Mass (ESI): 463.3 (M+Na)<sup>+</sup>

10

#### Preparation 13

To a solution of 2-(4-chlorophenyl)amino-2-methyl-1-(triphenylmethyl)amino-propane (2.79 g) in dichloromethane (100 ml) were added in sequence triethylamine (3.88 ml) and methyl oxalyl chloride (1.16 ml). After stirring at room temperature for 4 hours,

15 the mixture was washed with sodium hydrogen carbonate aqueous solution, dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel (ethyl acetate/hexane = 1/9 to 1/1) to give methyl

{{(4-chlorophenyl)-[1,1-dimethyl-2-((triphenylmethyl)amino)ethyl]amino}(oxo)acetate (3.3 g) as an oil.

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.28 (6H, s), 1.87 (1H, t, J=8.5 Hz), 2.63 (2H, d, J=8.5 Hz), 3.46 (3H, s), 7.10 - 7.70 (19H, m)

Mass (ESI): 549.3 (M+Na)<sup>+</sup>

#### Preparation 14

25 To a solution of methyl

{{(4-chlorophenyl)-[1,1-dimethyl-2-((triphenylmethyl)amino)ethyl]amino}(oxo)acetate (3.3 g) in dichloromethane were added in sequence anisole (3.3 ml) and trifluoroacetic acid (6 ml) at 0 °C. After stirring at this temperature for 2 hours, the mixture was diluted with water and extracted with dichloromethane twice. The combined extracts were dried over  
30 magnesium sulfate and concentrated. A suspension of the residue in 2-propanol (15 ml) was stirred at 80 °C in the presence of acetic acid (1 ml) for 2 hours. The mixture was cooled to 0 °C, and the resulting precipitates were collected, washed with 2-propanol and dried in vacuo (40°C) to give 1-(4-chlorophenyl)-6,6-dimethyl-2,3-piperazinedione (1.17 g).

35 <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.34 (6H, s), 3.55 (2H, d, J=3.3 Hz), 7.00 - 7.20 (3H, m), 7.43 (2H, d, J=8.6 Hz)

WO 03/063874

PCT/IP03/00708

Mass (ESI): 275.2 (M+Na)<sup>+</sup>

Preparation 15

To a suspension of 1-(4-chlorophenyl)-6,6-dimethyl-2,3-piperazinedione (0.69 g) in tetrahydrofuran (25 ml) was added dropwise 2M boran-methyl sulfide complex in tetrahydrofuran (6.8 ml) under nitrogen, and the mixture was stirred at room temperature overnight. The reaction was quenched with methanol and 12N aqueous hydrochloric acid (1.5 ml) was added. After stirring at 70 °C for 1 hour, the mixture was cooled to room temperature, basified with 1N aqueous sodium hydroxide and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was dissolved in dichloromethane, treated with 4N hydrogen chloride in ethyl acetate (1 ml) and concentrated to give 1-(4-Chlorophenyl)-2,2-dimethylpiperazine hydrochloride (0.46 g) as an amorphous powder.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.09 (6H, s), 2.90 - 3.40 (6H, m), 7.20 (2H, d, J=8.7 Hz), 7.38 (2H, d, J=8.7 Hz), 9.38 (2H, brs)  
Mass (ESI): 225.3 (M+H)<sup>+</sup>

Preparation 16

A mixture of 4-bromochlorobenzene (1.5 g), cis-2,6-dimethylpiperazine (1.07 g), trans-dichlorobis(tri-o-tolylphosphine)palladium (II) (185 mg), sodium t-butoxide (1.09 g) in toluene (20 ml) was stirred at 100 °C under nitrogen for 3 hours. After cooling to room temperature, the reaction was quenched with water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using 5% methanol in dichloromethane as an eluent to give 4-(4-Chlorophenyl)-cis-2,6-dimethylpiperazine (1.46 g) as a solid.

Mass (ESI): 225.3 (M+H)<sup>+</sup>

Preparation 17

A biphasic solution of (3R,5R)-1-benzyl-3,5-dimethylpiperazine (1.61 g; net: 1.50 g) and di-t-butylidicarbonate (1.61 g) in dichloromethane (20 ml) and 1N aqueous sodium hydroxide (20 ml) was stirred at room temperature for 30 minutes. The organic phase was separated and the aqueous layer was further extracted with dichloromethane. The combined extracts were dried over magnesium sulfate and concentrated in vacuo. The residue was dissolved in 20% ethyl acetate in hexane and treated with silica gel (7.5 g).

WO 03/063874

PCT/JP03/00708

Silica gel was removed by filtration and washed with 20% ethyl acetate in hexane twice, and then the combined filtrate was evaporated to afford colorless oil. A solution of the residue in methanol was hydrogenated over 10% palladium-on-charcoal (450 mg) for 3 hours. The catalyst was removed by filtration and the filtrate was concentrated. The  
5 residue was chromatographed on silica gel (20% ethyl acetate in hexane to 10% methanol in dichloromethane), and then the fractions eluted with 10% methanol in dichloromethane were combined and concentrated to give t-butyl  
(2R,6R)-2,6-dimethyl-1-piperazinecarboxylate (1.32 g) as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.30 (6H, d, J=6.6 Hz), 1.47 (9H, s), 2.71 (2H, dd, J=4.4,  
10 12.6 Hz), 3.15 (2H, dd, J=4.0, 12.6 Hz), 3.70 - 4.00 (2H, m)  
Mass (ESI): 237.3 (M+Na)<sup>+</sup>

#### Preparation 18

A mixture of t-butyl (2R,6R)-2,6-dimethyl-1-piperazinecarboxylate (1.27 g),  
15 4-bromochlorobenzene (3.4 g), tris(dibenzylideneacetone)dipalladium (0) (271 mg),  
2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (369 mg), sodium t-butoxide (2.28 g) in  
toluene (26 ml) was stirred at 80 °C under nitrogen overnight. The mixture was cooled,  
diluted with water and extracted with dichloromethane twice. The combined extracts  
were dried over magnesium sulfate and concentrated. The residue was dissolved in 20%  
20 ethyl acetate in hexane (50 ml) and treated with silica gel (20 g). Silica gel was removed  
by filtration and washed with 20% ethyl acetate in hexane (50 ml) twice, and then the  
combined filtrate was evaporated. To a solution of the residue in dichloromethane (30  
ml) was added dropwise trifluoroacetic acid at 0 °C. After stirring for 1 hour, the mixture  
was concentrated, basified with 1N aqueous sodium hydroxide and extracted with  
25 dichloromethane twice. The combined extracts were dried over magnesium sulfate and  
concentrated. The residue was chromatographed on silica gel (30 g) (50% ethyl acetate in  
hexane to 10% methanol in dichloromethane), and the fractions eluted with 10% methanol  
in dichloromethane were combined and concentrated. A solution of the residue in ethyl  
acetate was treated with 4N hydrogen chloride in ethyl acetate (2 ml), and the resulting  
30 powder was collected, washed with ethyl acetate and dried in vacuo to give  
(3R,5R)-1-(4-Chlorophenyl)-3,5-dimethylpiperazine hydrochloride (1.49 g).

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.34 (6H, d, J=6.6 Hz), 3.12 (2H, dd, J=6.4, 13.0 Hz),  
3.43 (2H, dd, J=3.3, 13.0 Hz), 6.99 (2H, d, J=9.0 Hz), 7.27 (2H, d, J=9.0 Hz), 9.48  
(2H, brs)  
35 Mass (ESI): 225.3 (M+H)<sup>+</sup>

WO 03/063874

PCT/JP03/00708

Preparation 19

The following compound was prepared in a similar manner to that of Preparation

17.

(1) *t*-Butyl (2*S*,6*S*)-2,6-dimethyl-1-piperazinecarboxylate

5 <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.30 (6H, d, J=6.6 Hz), 1.47 (9H, s), 2.71 (2H, dd, J=4.4, 12.6 Hz), 3.15 (2H, dd, J=4.0, 12.6 Hz), 3.70 - 4.00 (2H, m)

Mass (ESI): 237.3 (M+Na)<sup>+</sup>

Preparation 20

10 The following compound was prepared in a similar manner to that of Preparation

18.

(1) (3*S*,5*S*)-1-(4-Chlorophenyl)-3,5-dimethylpiperazine hydrochloride

15 <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, δ): 1.34 (6H, d, J=6.6 Hz), 3.12 (2H, dd, J=6.4, 13.0 Hz), 3.43 (2H, dd, J=3.3, 13.0 Hz), 6.99 (2H, d, J=9.0 Hz), 7.27 (2H, d, J=9.0 Hz), 9.48 (2H, brs)

Mass (ESI): 225.3 (M+H)<sup>+</sup>

Preparation 21

20 A mixture of 4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (6 g), 4-bromobutyronitrile (3.35 ml) and diisopropylethylamine (16 ml) in N,N-dimethylformamide (30 ml) was stirred at 80 °C for 3 hours. The mixture was diluted with water, extracted with ethyl acetate twice. The combined extracts were washed with water three times, dried over magnesium sulfate and concentrated. The residue was dissolved in ethyl acetate and treated with silica gel (30 g). Silica gel was removed by filtration and washed with ethyl acetate. The combined filtrate was concentrated to give 4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butanenitrile as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.75 - 2.10 (2H, m), 2.30 - 2.90 (8H, m), 3.05 - 3.25 (2H, m), 6.06 (1H, s), 7.10 - 7.80 (5H, m)

Mass (APCI): 227.40 (M+H)<sup>+</sup>

30

Preparation 22

35 To a suspension of ammonium chloride (2.95 g) in toluene (20 ml) was added dropwise 2*N* trimethylaluminum in toluene (27.5 ml) at 0 °C under nitrogen, and the mixture was stirred at room temperature for 2 hours. To this aluminum amide reagent was added dropwise 4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butanenitrile (2.5 g) in toluene (10 ml) at room temperature, and this solution was stirred at 80 °C overnight. The

WO 03/063874

PCT/JP03/00708

reaction mixture was carefully poured into a suspension of silica gel (60 g) in chloroform (180 ml). Silica gel was removed by filtration and washed with methanol (200 ml), and then the combined filtrate was concentrated. The residue was chromatographed on aluminum (68 g) using 20% methanol in dichloromethane as an eluent to give

5 4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butanimidamide (2.04 g) as an oil.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.10 - 2.90 (8H, m), 3.09 (2H, d, J=2.8 Hz), 6.16 (1H, s), 7.10 - 7.70 (5H, m), 8.69 (3H, brs)

Mass (APCI): 244.33 (M+H)<sup>+</sup>

#### 10 Preparation 23

The following compounds were prepared in a similar manner to that of Preparation 21.

- (1) 4-[4-(3,4-Difluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
15 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 2.00 (2H, m), 2.20 - 2.80 (8H, m), 3.07 (2H, d, J=2.6 Hz), 6.04 (1H, s), 7.00 - 7.80 (3H, m)  
Mass (ESI): 263.3 (M+H)<sup>+</sup>
- (2) 4-[4-(4-Chlorophenyl)-2,2-dimethyl-1-piperazinyl]butanenitrile  
20 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.08 (6H, s), 1.50 - 1.80 (2H, m), 2.20 - 2.70 (6H, m), 2.87 (2H, s), 3.00 - 3.20 (2H, m), 6.91 (2H, d, J=9.1 Hz), 7.20 (2H, d, J=9.1 Hz)  
Mass (ESI): 292.3 (M+H)<sup>+</sup>
- (3) 4-[(2S)-4-(4-Chlorophenyl)-2-methyl-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.05 (3H, d, J=5.6 Hz), 1.60 - 1.90 (2H, m), 2.00 - 3.60 (11H, m), 6.93 (2H, d, J=9.1 Hz), 7.21 (2H, d, J=9.1 Hz)  
Mass (ESI): 278.2 (M+H)<sup>+</sup>
- 25 (4) 4-[4-(4-Chlorophenyl)-3,3-dimethyl-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.98 (6H, s), 1.60 - 1.90 (2H, m), 2.20 - 3.20 (10H, m), 7.10 (2H, d, J=8.8 Hz), 7.29 (2H, d, J=8.8 Hz)  
Mass (ESI): 292.4 (M+H)<sup>+</sup>
- 30 (5) 4-[(2R,6S)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.16 (6H, s), 1.60 - 3.60 (12H, m), 6.82 (2H, d, J=9.0 Hz), 7.19 (2H, d, J=9.0 Hz)  
Mass (ESI): 292.4 (M+H)<sup>+</sup>
- 35 (6) 4-[(2R,6R)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.01 (6H, d, J=6.1 Hz), 1.50 - 1.80 (2H, m), 2.20 - 3.30 (10H, m), 6.91 (2H, d, J=9.0 Hz), 7.20 (2H, d, J=9.0 Hz)  
Mass (ESI): 292.2 (M+H)<sup>+</sup>

WO 03/063874

PCT/JP03/00708

- (7) 4-[(2S,6S)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.01 (6H, d, J=6.1 Hz), 1.50 - 1.80 (2H, m), 2.20 - 3.30 (10H, m), 6.91 (2H, d, J=9.0 Hz), 7.20 (2H, d, J=9.0 Hz)  
Mass (ESI): 292.2 (M+H)<sup>+</sup>
- 5 (8) 4-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 2.00 (2H, m), 2.20 - 2.80 (8H, m), 3.06 (2H, d, J=3.0 Hz), 6.12 (1H, t, J=3.0 Hz), 7.00 - 7.70 (4H, m)  
Mass (ESI): 245.4 (M+H)<sup>+</sup>
- 10 (9) 4-[4-(4-chlorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 1.90 (2H, m), 2.30 - 3.20 (10H, m), 6.19 (1H, t, J=3.5 Hz), 7.30 - 7.70 (4H, m)  
Mass (APCI): 261.07 (M+H)<sup>+</sup>
- 15 (10) 4-[4-(4-Methylphenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 1.90 (2H, m), 2.28 (3H, s), 2.30 - 2.80 (8H, m), 3.07 (2H, d, J=2.7 Hz), 6.09 (1H, s, J=2.7 Hz), 7.13 (2H, d, J=8.0 Hz), 7.31 (2H, d, J=8.0 Hz)  
Mass (APCI): 241.33 (M+H)<sup>+</sup>
- 20 (11) 4-[4-(4-Trifluoromethylphenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 3.20 (10H, m), 6.33 (1H, s), 7.50 - 7.70 (4H, m)  
Mass (APCI): 295.00 (M+H)<sup>+</sup>
- 25 (12) 4-[4-(4-Methoxyphenyl)-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 2.80 (8H, m), 3.74 (3H, s), 6.03 (1H, s), 6.89 (2H, d, J=8.8 Hz), 7.36 (2H, d, J=8.8 Hz)  
Mass (APCI): 257.27 (M+H)<sup>+</sup>
- 30 (13) 4-[4-(4-Chlorophenyl)-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 1.90 (2H, m), 2.30 - 2.80 (8H, m), 3.12 (4H, t, J=5.0 Hz), 6.94 (2H, d, J=9.1 Hz), 7.22 (2H, d, J=9.1 Hz)  
Mass (APCI): 264.47 (M+H)<sup>+</sup>
- 30 (14) 4-[4-(4-Fluorophenyl)-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 2.00 (2H, m), 2.30 - 2.80 (8H, m), 3.07 (4H, t, J=5.0 Hz), 6.80 - 7.20 (4H, m)  
Mass (ESI): 248.3 (M+H)<sup>+</sup>
- 35 (15) 4-[4-(4-Nitrophenyl)-1-piperazinyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 1.90 (2H, m), 2.20 - 2.80 (8H, m), 3.45 (4H, t, J=5.0 Hz), 7.03 (2H, d, J=9.4 Hz), 8.05 (2H, d, J=9.4 Hz)

WO 03/063874

PCT/JP03/00708

Mass (ESI): 275.3 (M+H)<sup>+</sup>Preparation 24

The following compounds were prepared in a similar manner to that of

5 Preparation 22.

- (1) 4-[4-(3,4-Difluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.30 (10H, m), 6.05 (1H, s),  
 7.00 - 7.70 (3H, m)  
 Mass (ESI): 280.4 (M+H)<sup>+</sup>
- 10 (2) 4-[4-(4-Chlorophenyl)-2,2-dimethyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.03 (6H, s), 1.50 - 1.90 (2H, m), 2.20 - 3.30 (10H, m),  
 6.92 (2H, d, J=9.0 Hz), 7.21 (2H, d, J=9.0 Hz), 8.45 (3H, brs)  
 Mass (ESI): 309.3 (M+H)<sup>+</sup>
- 15 (3) 4-[(2S)-4-(4-Chlorophenyl)-2-methyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.04 (3H, d, J=5.5 Hz), 1.60 - 2.00 (2H, m), 2.00 - 3.70  
 (11H, m), 6.93 (2H, d, J=9.0 Hz), 7.22 (2H, d, J=9.0 Hz), 8.68 (3H, brs)  
 Mass (ESI): 295.4 (M+H)<sup>+</sup>
- 20 (4) 4-[4-(4-Chlorophenyl)-3,3-dimethyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.99 (6H, s), 1.60 - 1.90 (2H, m), 2.10 - 3.20 (10H, m),  
 7.10 (2H, d, J=8.8 Hz), 7.30 (2H, d, J=8.8 Hz), 9.03 (3H, brs)  
 Mass (ESI): 309.3 (M+H)<sup>+</sup>
- 25 (5) 4-[(2R,6S)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.06 (6H, d, J=6.2 Hz), 1.50 - 1.90 (2H, m), 2.10 - 3.90  
 (10H, m), 6.92 (2H, d, J=9.1 Hz), 7.21 (2H, d, J=9.1 Hz)  
 Mass (ESI): 309.3 (M+H)<sup>+</sup>
- 30 (6) 4-[(2R,6R)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.01 (6H, d, J=6.1 Hz), 1.50 - 1.90 (2H, m), 2.20 - 3.30  
 (10H, m), 6.92 (2H, d, J=9.0 Hz), 7.21 (2H, d, J=9.0 Hz), 8.79 (3H, brs)  
 Mass (ESI): 309.3 (M+H)<sup>+</sup>
- 30 (7) 4-[(2S,6S)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.01 (6H, d, J=6.1 Hz), 1.50 - 1.90 (2H, m), 2.20 - 3.30  
 (10H, m), 6.92 (2H, d, J=9.0 Hz), 7.21 (2H, d, J=9.0 Hz), 8.79 (3H, brs)  
 Mass (ESI): 309.3 (M+H)<sup>+</sup>
- 35 (8) 4-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 2.80 (8H, m), 3.08 (2H, d,  
 J=2.9 Hz), 6.13 (1H, s), 7.10 - 7.60 (4H, m)



WO 03/063874

PCT/JP03/00708

- Mass (ESI): 262.4 (M+H)<sup>+</sup>
- (9) 4-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.80 (8H, m), 3.09 (2H, d, J=2.8 Hz), 6.21 (1H, s), 7.20 - 7.60 (4H, m)
- 5 Mass (APCI): 278.07 (M+H)<sup>+</sup>
- (10) 4-[4-(4-Methylphenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.28 (3H, s), 2.30 - 2.70 (8H, m), 3.08 (2H, d, J=2.7 Hz), 6.11 (1H, s), 7.14 (2H, d, J=8.2 Hz), 7.32 (2H, d, J=8.2 Hz)
- 10 Mass (APCI): 258.33 (M+H)<sup>+</sup>
- (11) 4-[4-(4-(Trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.80 (10H, m), 6.35 (1H, s), 7.50 - 7.90 (4H, m), 8.53 (3H, brs)
- 15 Mass (ESI): 312.3 (M+H)<sup>+</sup>
- (12) 4-[4-(4-Methoxyphenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 2.80 (8H, m), 3.06 (2H, d, J=3.0 Hz), 3.74 (3H, s), 6.04 (1H, s), 6.90 (2H, d, J=8.8 Hz), 7.36 (2H, d, J=8.8 Hz)
- 20 Mass (APCI): 274.27 (M+H)<sup>+</sup>
- (13) 4-[4-(4-Chlorophenyl)-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.70 (8H, m), 2.90 - 3.30 (4H, m), 6.94 (2H, d, J=9.1 Hz), 7.23 (2H, d, J=9.1 Hz), 8.97 (3H, brs)
- Mass (APCI): 281.20 (M+H)<sup>+</sup>
- (14) 4-[4-(4-Fluorophenyl)-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.80 (8H, m), 3.05 (4H, t, J=5.0 Hz), 6.80 - 7.20 (4H, m), 8.80 (3H, brs)
- 25 Mass (ESI): 265.4 (M+H)<sup>+</sup>
- (15) 4-[4-(4-Nitrophenyl)-1-piperazinyl]butanimidamide  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 4.00 (14H, m), 7.02 (2H, d, J=9.4 Hz), 8.06 (2H, d, J=9.4 Hz)
- 30 Mass (ESI): 292.4 (M+H)<sup>+</sup>

#### Preparation 25

To a solution of 4-(4-phenyl)-3,6-dihydro-1(2H)-pyridyl)butanenitrile (0.75 g) in  
 35 toluene was added dropwise 1N diisobutylaluminum hydride in hexane (6.63 ml) at  
 -78 °C, and the mixture was warmed up to 0 °C. The reaction was quenched with 1N

WO 03/063874

PCT/JP03/00708

aqueous hydrochloric acid, basified with saturated aqueous sodium hydrogen carbonate. The mixture was filtered through celite and the filter cake was washed with dichloromethane, then the combined filtrate was dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel (80% ethyl acetate in

5 hexane to 10% methanol in dichloromethane) to give

4-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)butanal (0.4 g) as an oil.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ,  $\delta$ ): 1.90 - 2.30 (2H, m), 2.40 - 2.60 (2H, m), 2.70 - 2.85 (2H, m), 2.85 - 3.10 (2H, m), 3.50 - 3.70 (2H, m), 6.04 (1H, m), 7.10 - 7.60 (5H, m)

Mass (APCI): 230.27 ( $\text{M}+\text{H}$ ) $^+$

10

#### Preparation 26

A slurry of 4-benzyloxybutanal, (3-oxo-1,3-dihydro-2-benzofuran-1-yl)-(triphenyl)phosphonium bromide (560 mg) and triethylamine (7.39 ml) in tetrahydrofuran (50 ml) was stirred at room temperature overnight. The resulting precipitates were

15 removed by filtration and washed with ethyl acetate, and then the combined filtrate was concentrated. The residue was chromatographed on silica gel using toluene as an eluent to give an oil, which was dissolved in ethanol and refluxed in the presence of hydrazine monohydrate (1.4 g) for 1 hour. The mixture was concentrated, then dichloromethane and water were added and the organic layer was separated. The aqueous layer was further

20 extracted with dichloromethane, and then the combined extracts were dried over magnesium sulfate and concentrated. The residue was triturated with dichloromethane and diisopropylether, and then the resulting powder was collected, washed with diisopropylether and dried in vacuo to give 4-[4-(Benzyloxy)butyl]-1(2H)-phthalazinone (2.78 g).

25  $^1\text{H}$  NMR ( $\text{DMSO}-d_6$ ,  $\delta$ ): 1.50 - 2.00 (4H, m), 2.94 (2H, t,  $J=7.2$  Hz), 3.49 (2H, t,  $J=6.1$  Hz), 4.45 (2H, s), 7.10 - 7.50 (5H, m), 7.70 - 8.20 (3H, m), 8.26 (1H, dd,  $J=1.9, 7.1$  Hz), 12.45 (1H, brs)

Mass (ESI): 309.3 ( $\text{M}+\text{H}$ ) $^+$

#### 30 Preparation 27

To slurry of 4-[4-(benzyloxy)butyl]-1(2H)-phthalazinone in dichloromethane (5 ml) was added dropwise 1M boron tribromide in dichloromethane (0.97 ml), and the mixture was stirred at room temperature for 2 hours. The reaction was quenched with water and extracted with dichloromethane twice. The combined extracts were dried over

35 magnesium sulfate and concentrated. The residue was triturated with diisopropylether, and the resulting powder was collected, washed with diisopropylether and dried in vacuo to

WO 03/063874

PCT/JP03/00708

give 4-(4-Bromobutyl)-1(2H)-phthalazinone.

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.70 - 2.10 (4H, m), 2.96 (2H, t,  $J=7.3$  Hz), 3.61 (2H, t,  $J=6.4$  Hz), 7.70 - 8.10 (3H, m), 8.27 (1H, d,  $J=8.2$  Hz), 12.47 (1H, brs)  
Mass (ESI): 305.0 (M+Na) $^+$

5

The following compounds were prepared in a similar manner to that of

Preparation 26.

Preparation 28

(1) 4-[5-(Benzyloxy)pentyl]-1(2H)-phthalazinone

10  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.40 - 2.00 (6H, m), 2.80 - 3.70 (4H, m), 4.32 (2H, s),  
7.20 - 7.50 (5H, m), 7.70 - 8.10 (3H, m), 8.27 (1H, d,  $J=7.4$  Hz), 12.44 (1H, brs)  
Mass (ESI): 345.3 (M+Na) $^+$

Preparation 29

15 (1) 4-(5-Bromopentyl)-1(2H)-phthalazinone

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.30 - 2.00 (6H, m), 2.93 (2H, t,  $J=7.5$  Hz), 3.54 (2H, t,  $J=6.7$  Hz), 7.70 - 8.20 (3H, m), 8.27 (1H, d,  $J=7.3$  Hz), 12.45 (1H, brs)  
Mass (ESI): 317.1 (M+Na) $^+$

20 Preparation 30

50% Pd/C catalyst (50% wet, 400mg) was added to a solution of  
4-(4-biphenyl)-1,2,3,6-tetrahydropyridine (470mg) in a mixture of tetrahydrofuran  
(10ml), methanol (20ml) and acetic acid (10ml). The mixture was stirred under hydrogen  
at atmospheric pressure until gas absorption ceased. After filtration through celite and  
25 removal of solvent, the residue was dissolved in a mixture of ethyl acetate and aqueous  
sodium hydrogen carbonate. The aqueous phase was separated and the organic phase was  
washed with brine and dried over magnesium sulfate. Evaporation of the solvent afforded  
4-(4-biphenyl)piperidine (432mg).

Mass: 238.1 (M+H) $^+$

30

Preparation 31

To a solution of 4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridine (1 g) and ethyl  
4-oxopentanoate (0.961 ml) in toluene was added a catalytic amount of p-toluenesulfonic  
acid (54 mg), and the mixture was stirred under reflux to remove liberated water  
35 azeotropically. After stirring for 3 hours, the mixture was cooled and diluted with  
dichloroethane. To the mixture were added sodium tri(acetoxy)borohydride (3.59 g) and

WO 03/063874

PCT/JP03/00708

acetic acid (0.97 ml) in sequence, and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with water, neutralized and extracted with dichloromethane three times. The combined extracts were dried over magnesium sulfate and concentrated. The residue was chromatographed on silica gel using ethyl acetate as an eluent to give Ethyl 4-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]-4-methylbutanoate (0.72 g).  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.80 - 4.30(19H, m), 6.13(1H, m), 6.80 - 7.60(4H, m).  
Mass(ESI): 306.3 (M+H)<sup>+</sup>

#### 10 Preparation 32

A mixture of 4-[4-(trifluoromethyl)phenyl]piperidine hydrochloride (1.18 g), 4-bromobutyronitrile (0.662 ml) and triethylamine (1.86 ml) in N,N-dimethylformamide (20 ml) was stirred at 80 °C overnight. The mixture was diluted with water, extracted with ethyl acetate twice. The combined extracts were washed with water three times, dried over magnesium sulfate and concentrated. The residue was dissolved in ethyl acetate and treated with silica gel (10 g). Silica gel was removed by filtration and washed with ethyl acetate. The combined filtrate was concentrated to give 4-[4-[4-(trifluoromethyl)phenyl]piperidino]butanenitrile as an oil.  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 3.20(15H, m), 7.48(2H, d, J=8.2 Hz), 7.65(2H, d).  
Mass(ESI): 297.2 (M+H)<sup>+</sup>

The following compound was obtained according to a similar manner to that of Preparation 32.

#### 25 Preparation 33

4-[4-[4-(Trifluoromethoxy)phenyl]-3,6-dihydro-1(2H)-pyridyl]butanenitrile  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.60 - 3.30(12H, m), 6.20(1H, m), 7.00 - 7.80(4H, m).  
Mass(ESI): 311.2 (M+H)<sup>+</sup>

#### 30 Preparation 34

Under a nitrogen atmosphere, 4-bromobutanenitrile (402mg) and triethylamine (0.76ml) was added successively to a suspension of 4-(4-biphenyl)pyperidine (430mg) in N,N-dimethylformamide (5ml) at room temperature. The mixture was stirred for 15 hours at 80°C and cooled to room temperature. The mixture was poured into a mixture of water and chloroform and the aqueous layer was separated. The organic layer was washed with brine and dried over magnesium sulfate. The solvent was evaporated and the residue

WO 03/063874

PCT/JP03/00708

was purified by column chromatography on silica gel eluting with dichloromethane-acetone to afford 4-[4-(4-biphenyl)piperidino]butanenitrile (411mg).  
Mass: 305.2 (M+H)<sup>+</sup>

5 The following compounds [Preparations 35 and 36] were obtained according to a similar manner to that of Preparation 34.

Preparation 35

4-[4-(3,4-dichlorophenyl)-1-piperazinyl]butanenitrile

10 <sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.85(2H, m), 2.4-2.7(8H, m), 3.1-3.2(4H, m), 6.72(1H, dd, J=9.0, 3.0 Hz), 6.95(1H, d, J=3.0 Hz), 7.28(1H, d, J=9.0 Hz).  
Mass: 320.0, 322.1 (M+Na)<sup>+</sup>

Preparation 36

15 4-[4-(4-biphenyl)-1,2,3,6-tetrahydropyridyl]butanenitrile  
Mass: 303.2 (M+H)<sup>+</sup>

Preparation 37

To a suspension of ammonium chloride (1.09 g) in toluene (20 ml) was added  
20 dropwise 2N trimethylaluminium in toluene (10.2 ml) at 0 °C under nitrogen, and the mixture was stirred at room temperature for 2 hours. To this aluminum amide reagent was added dropwise 4-[4-(4-(trifluoromethyl)phenyl)piperidino]butanenitrile (1.21 g) in toluene (20 ml) at room temperature, and this solution was stirred at 80 °C overnight. The reaction mixture was carefully poured into a suspension of silica gel (15 g) in  
25 chloroform (40 ml). Silica gel was removed by filtration and washed with methanol (50 ml) twice, and the combined filtrate was concentrated. The residue was chromatographed on alumina (30 g) (methanol/dichloromethane = 1/4) to give  
4-[4-[4-(trifluoromethyl)phenyl]piperidino]butanamide (1.40 g) as an oil.  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.30 - 3.80(15H, m), 7.49(2H, d, J=7.9 Hz), 7.70(2H, d, J=7.9  
30 Hz), 8.75(3H, brs).  
Mass(ESI): 314.4 (M+H)<sup>+</sup>

The following compounds [Preparation 38 to 42] were obtained according to a similar manner to that of Preparation 37.

35

Preparation 38

WO 03/063874

PCT/JP03/00708

4-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]-4-methylbutanamide

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.80 - 4.40(14H, m), 6.15(1H, m), 6.90 - 7.70(4H, m), 8.80(3H, brs).Mass(ESI): 276.2 (M+H)<sup>+</sup>

5

Preparation 39

4-[4-[4-(Trifluoromethoxy)phenyl]-3,6-dihydro-1(2H)-pyridyl]butanamide

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.50 - 4.00(12H, m), 6.22(1H, m), 7.32(2H, d, J=8.2 Hz),  
10 7.56(2H, d, J=8.2 Hz).Mass(ESI): 328.3 (M+H)<sup>+</sup>Preparation 40

To a solution of 4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridine (1 g) and ethyl  
15 4-oxopentanoate (0.961 ml) in toluene was added a catalytic amount of p-toluenesulfonic  
acid (54 mg), and the mixture was stirred under reflux to remove liberated water  
azeotropically. After stirring for 3 hours, the mixture was cooled and diluted with  
dichloroethane. To the mixture were added sodium tri(acetoxy)borohydride (3.59 g) and  
acetic acid (0.97 ml) in sequence, and the mixture was stirred at room temperature for 1  
20 hour. The mixture was diluted with water, neutralized and extracted with  
dichloromethane three times. The combined extracts were dried over magnesium sulfate  
and concentrated. The residue was chromatographed on silica gel using ethyl acetate as  
an eluent to give Ethyl 4-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]pentanoate (0.72  
g)

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.80 - 4.30(19H, m), 6.13(1H, m), 6.80 - 7.60(4H, m).25 Mass(ESI): 306.3 (M+H)<sup>+</sup>Preparation 41

4-[4-(3,4-dichlorophenyl)-1-piperazinyl]butanamide

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.6-1.9(2H, m), 2.2-2.6(8H, m), 3.1-3.3(4H, m), 6.94(1H, dd,  
30 J=9.0, 2.5 Hz), 7.15(1H, d, J=2.5 Hz), 7.39(1H, d, J=9.0 Hz).Mass: 316.2 (M+H)<sup>+</sup>Preparation 42

35 4-[4-(4-biphenyl)-1,2,3,6-tetrahydropyridyl]butanamide

Mass: 320.1 (M+H)<sup>+</sup>

WO 03/063874

PCT/JP03/00708

Example 1

A suspension of 4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butanimidamide (107 mg), cyclohexanone-2-carboxylic acid ethyl ester (50 mg), potassium carbonate (568 mg) in ethanol (5 ml) was stirred at 80 °C overnight. The mixture was diluted with water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography on silica gel using 10% methanol in dichloromethane as an eluent to give 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone (58 mg) as a colorless powder.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.40 - 2.20 (6H, m), 2.30 - 3.00 (10H, m), 3.10 - 3.40 (2H, m), 6.10 (1H, s), 7.10 - 7.60 (5H, m)

Mass (APCI): 350.20 (M+H)<sup>+</sup>

15 Example 2

The following compounds were prepared in a similar manner to that of Example 1.

## 1.

(1) 2-{3-[4-(4-Chlorophenyl)-2,2-dimethyl-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.02 (6H, s), 1.40 - 1.90 (6H, m), 2.10 - 2.70 (10H, m), 2.83 (2H, s), 2.90 - 3.20 (2H, m), 6.89 (2H, d, J=9.0 Hz), 7.20 (2H, d, J=9.0 Hz), 12.28 (1H, brs)

Mass (ESI): 415.4 (M+H)<sup>+</sup>

(2) 2-{3-[4-(4-Chlorophenyl)-2-methyl-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.02 (3H, d, J=5.3 Hz), 1.40 - 3.60 (21H, m), 6.91 (2H, d, J=9.1 Hz), 7.20 (2H, d, J=9.1 Hz), 12.18 (1H, brs)

Mass (ESI): 401.2 (M+H)<sup>+</sup>

(3) 2-{3-[4-(4-Chlorophenyl)-3,3-dimethyl-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.96 (6H, s), 1.50 - 2.00 (2H, m), 2.00 - 3.20 (14H, m), 7.07 (2H, d, J=8.7 Hz), 7.29 (2H, d, J=8.7 Hz), 12.13 (1H, brs)

Mass (ESI): 415.4 (M+H)<sup>+</sup>

(4) 2-{3-[4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.06 (6H, d, J=6.0 Hz), 1.40 - 1.90 (6H, m), 2.10 - 3.80

WO 03/063874

PCT/JP03/00708

- (12H, m), 6.92 (2H, d, J=9.0 Hz), 7.20 (2H, d, J=9.0 Hz), 12.18 (1H, brs)  
Mass (ESI): 415.4 (M+H)<sup>+</sup>
- (5) 2-{3-[(2R,6R)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
5 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.99 (6H, d, J=6.1 Hz), 1.40 - 2.00 (6H, m), 2.10 - 3.30  
(14H, m), 6.90 (2H, d, J=8.9 Hz), 7.20 (2H, d, J=8.9 Hz), 12.18 (1H, brs)  
Mass (ESI): 415.4 (M+H)<sup>+</sup>
- (6) 2-{3-[(2S,6S)-4-(4-Chlorophenyl)-2,6-dimethyl-1-piperazinyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
10 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 0.99 (6H, d, J=6.1 Hz), 1.40 - 2.00 (6H, m), 2.10 - 3.30  
(14H, m), 6.90 (2H, d, J=8.9 Hz), 7.20 (2H, d, J=8.9 Hz), 12.18 (1H, brs)  
Mass (ESI): 415.4 (M+H)<sup>+</sup>
- (7) 2-{3-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
15 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.10 - 2.70 (12H, m), 3.04 (2H, d,  
J=2.6 Hz), 6.09 (1H, s), 7.00 - 7.60 (4H, m), 12.11 (1H, brs)  
Mass (APCI): 368.20 (M+H)<sup>+</sup>
- (8) 2-{3-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
20 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.20 - 2.80 (12H, m), 3.04 (2H, d,  
J=3.0 Hz), 6.17 (1H, s), 7.20 - 7.60 (4H, m), 12.11 (1H, brs)  
Mass (ESI): 384.3 (M+H)<sup>+</sup>
- (9) 2-{3-[4-(4-Methylphenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
25 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.10 - 2.80 (15H, m), 3.04 (2H, m),  
6.07 (1H, s), 7.12 (2H, d, J=8.0 Hz), 7.30 (2H, d, J=8.0 Hz), 12.09 (1H, brs)  
Mass (ESI): 364.4 (M+H)<sup>+</sup>
- (10) 2-{3-[4-(4-(Trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
30 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.45 - 1.75 (4H, m), 1.80 - 2.00 (2H, m), 2.10 - 2.80  
(12H, m), 3.08 (2H, d, J=1.4 Hz), 6.31 (1H, s), 7.50 - 7.80 (4H, m)  
Mass (ESI): 418.3 (M+H)<sup>+</sup>
- (11) 2-{3-[4-(4-Methoxyphenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-  
5,6,7,8-tetrahydro-4(3H)-quinazolinone  
35 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.10 - 3.20 (12H, m), 3.74 (3H, s),  
6.00 (1H, s), 6.88 (2H, d, J=8.8 Hz), 7.34 (2H, d, J=8.8 Hz), 12.08 (1H, brs)



WO 03/063874

PCT/JP03/00708

Mass (APCI): 380.20 (M+H)<sup>+</sup>

- (12) 2-{3-[4-(4-Chlorophenyl)-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.00 - 3.70 (16H, m), 6.91 (2H, d, J=9.0 Hz), 7.21 (2H, d, J=9.0 Hz), 12.17 (1H, brs)

Mass (APCI): 387.07 (M+H)<sup>+</sup>

- (13) 2-{3-[4-(4-Fluorophenyl)-1-piperazinyl]propyl}-5,6,7,8-tetrahydro-4(3H)-quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (6H, m), 2.10 - 3.20 (16H, m), 6.80 - 7.20 (4H, m), 12.16 (1H, brs)

Mass (APCI): 371.07 (M+H)<sup>+</sup>

### Example 3

The following compounds were prepared in a similar manner to that of Example

1.15

- (1) 2-{3-[4-(3,4-Difluorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 3.00 (12H, m), 3.07 (2H, d, J=2.9 Hz), 3.40 (2H, s), 6.02 (1H, s), 7.00 - 7.60 (3H, m), 12.35 (1H, brs)

Mass (ESI): 404.2 (M+H)<sup>+</sup>

- (2) 2-{3-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.80 (4H, m), 3.04 (2H, d, J=2.8 Hz), 6.09 (1H, s), 7.00 - 7.60 (4H, m), 12.34 (1H, brs)

Mass (APCI): 386.00 (M+H)<sup>+</sup>

- (3) 2-{3-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.20 (16H, m), 6.17 (1H, s), 7.20 - 7.60 (4H, m), 12.35 (1H, brs)

Mass (APCI): 401.93 (M+H)<sup>+</sup>

- (4) 2-{3-[4-(4-Methylphenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.27 (3H, s), 2.30 - 2.90 (12H, m), 3.03 (2H, d, J=2.8 Hz), 3.38 (2H, s), 6.07 (1H, s), 7.12 (2H, d, J=8.2 Hz), 7.30 (2H, d, J=8.2 Hz), 12.35 (1H, brs)

Mass (APCI): 382.13 (M+H)<sup>+</sup>

WO 03/063874

PCT/JP03/00708

- (5) 2-{3-[4-(4-(Trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.30 - 3.00 (14H, m), 3.08 (2H, d, J=2.5 Hz), 6.31 (1H, s), 7.40 - 7.80 (4H, m)  
5 Mass (APCI): 434.33 (M-H)<sup>-</sup>
- (6) 2-{3-[4-(4-Methoxyphenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.20 (14H, m), 3.38 (2H, s), 3.74 (3H, s), 6.00 (1H, s), 6.88 (2H, d, J=8.8 Hz), 7.34 (2H, d, J=8.8 Hz), 12.36 (1H, brs)  
10 Mass (ESI): 398.3 (M+H)<sup>+</sup>
- (7) 2-{3-[4-(4-Chlorophenyl)-1-piperazinyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.20 (16H, m), 3.40 (2H, s), 6.92 (2H, d, J=9.1 Hz), 7.21 (2H, d, J=9.1 Hz), 12.36 (1H, brs)  
15 Mass (APCI): 405.3 (M+H)<sup>+</sup>
- (8) 2-{3-[4-(4-Fluorophenyl)-1-piperazinyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.90 (12H, m), 3.01 (4H, t, J=4.6 Hz), 3.40 (2H, s), 6.80 - 7.20 (4H, m), 12.43 (1H, brs)  
20 Mass (APCI): 389.2 (M+H)<sup>+</sup>
- (9) 2-{3-[4-(4-Nitrophenyl)-1-piperazinyl]propyl}-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.00 (16H, m), 3.40 (2H, s), 7.02 (2H, d, J=9.4 Hz), 8.05 (2H, d, J=9.4 Hz), 12.41 (1H, brs)  
25 Mass (ESI): 416.2 (M+H)<sup>+</sup>
- (10) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.90 (16H, m), 6.12 (1H, s), 7.10 - 7.60 (5H, m), 12.38 (1H, brs)  
30 Mass (APCI): 368.07 (M+H)<sup>+</sup>
- (11) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 3.80 (16H, m), 6.15 (1H, s), 7.00 - 7.60 (5H, m)  
35 Mass (ESI): 351.3 (M+H)<sup>+</sup>

WO 03/063874

PCT/JP03/00708

- (12) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.00 (2H, m), 2.20 - 2.80 (10H, m), 3.07 (2H, s), 3.80 (2H, t, J=5.5 Hz), 4.29 (2H, s), 6.12 (1H, s), 7.10 - 7.70 (5H, m)  
5 Mass (APCI): 352.2 (M+H)<sup>+</sup>

Example 4

The following compounds were prepared in a similar manner to that of Example

1. (1) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-3,5,6,7-tetrahydro-4H-cyclopenta[d]pyrimidin-4-one  
<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.70 - 2.30 (4H, m), 2.40 - 3.40 (14H, m), 6.06 (1H, s), 7.00 - 7.60 (5H, m)  
Mass (APCI): 336.20 (M+H)<sup>+</sup>
- 15 (2) 2-[3-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-3,5,6,7,8,9-hexahydro-4H-cyclohepta[d]pyrimidin-4-one  
<sup>1</sup>H NMR (CDCl<sub>3</sub>, δ): 1.00 - 2.40 (8H, m), 2.40 - 3.40 (14H, m), 6.07 (1H, s), 7.00 - 7.60 (5H, m)  
Mass (APCI): 364.20 (M+H)<sup>+</sup>
- 20 (3) 2-{3-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-7,8-dihydro-3H-thiopyrano[3,2-d]pyrimidin-4(6H)-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 2.20 (2H, m), 2.30 - 3.20 (14H, m), 6.10 (1H, s), 7.00 - 7.60 (4H, m), 12.37 (1H, brs)  
Mass (ESI): 386.2 (M+H)<sup>+</sup>

25

Example 5

A mixture of 4-[4-(4-fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butanimidamide (90 mg) and 2H-pyrido-[2,3-d][1,3]oxazine-2,4(1H)-dione (79 mg) in pyridine (5 ml) was stirred at 120 °C overnight. The mixture was concentrated and coevaporated with  
30 toluene twice. The residue was purified by preparative thin layer chromatography using 10% methanol in dichloromethane as an eluent to give 2-{3-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]propyl}-pyrido[2,3-d]pyrimidin-4(3H)-one, which was converted to the corresponding hydrochloride salt (40 mg) by treatment of 4N hydrogen chloride in ethyl acetate.

- 35 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 2.00 - 5.30 (12H, m), 6.18 (1H, s), 7.00 - 7.80 (5H, m), 8.55 (1H, dd, J=2.0, 8.0 Hz), 8.93 (1H, dd, J=2.0, 4.7 Hz)

WO 03/063874

PCT/JP03/00708

Mass (ESI): 365.5 (M+H)<sup>+</sup>Example 6

To a solution of 2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-  
5 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one (28 mg) in dichloromethane (5 ml)  
and methanol (1 ml) were added 37% aqueous formaldehyde (0.063 ml) and sodium  
triacetoxyborohydride (51 mg) in sequence, then the mixture was stirred at room  
temperature for 2 hours. The reaction was quenched with silica gel (0.2 g) and  
concentrated. The residue was chromatographed on silica gel (20% methanol in  
10 dichloromethane) to give 6-Methyl-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)propyl]-  
5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one the objective compound as a brown  
powder.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.70 - 3.20 (21H, m), 6.11 (1H, s), 7.00 - 7.50 (5H, m),  
12.26 (1H, brs)

15 Mass (ESI): 365.4 (M+H)<sup>+</sup>

Example 7

A suspension of 4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butanal (0.18 g),  
(3-oxo-1,3-dihydro-2-benzofuran-1-yl)(triphenyl)phosphonium bromide (560 mg) and  
20 triethylamine (0.328 ml) in tetrahydrofuran (20 ml) was stirred at room temperature for 3  
hours. The reaction was quenched with water and extracted with ethyl acetate twice.  
The combined extracts were dried over magnesium sulfate and concentrated. The residue  
was chromatographed on silica gel using ethyl acetate as an eluent to give oil, which was  
dissolved in ethanol and refluxed in the presence of hydrazine monohydrate (77 mg) for 1  
25 hour. The mixture was concentrated, then dichloromethane and water was added and the  
organic layer was separated. The aqueous layer was further extracted with  
dichloromethane, then the combined extracts were dried over magnesium sulfate and  
concentrated. The residue was chromatographed on silica gel (ethyl acetate to 5%  
methanol in dichloromethane), and then the fractions eluted with 5% methanol in  
30 dichloromethane were combined and concentrated. The residue was triturated with a  
mixture of ethyl acetate and diisopropyl ether to give  
4-[4-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)butyl]-1(2H)-phthalazinone (46 mg) as a pale  
yellow powder.

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.10 - 1.90 (4H, m), 2.30 - 3.00 (8H, m), 3.07 (2H, d,  
J=2.8 Hz), 6.15 (1H, s), 7.10 - 8.40 (9H, m), 12.45 (1H, brs)

35 Mass (APCI): 360.07 (M+H)<sup>+</sup>

WO 03/063874

PC1/JP03/00708

Example 8

A mixture of 4-(4-Bromobutyl)-1(2H)-phthalazinone (100 mg), 4-fluorophenyl-1,2,5,6-tetrahydropyridine hydrochloride (91 mg) and triethylamine (0.149 ml) in N,N-dimethylformamide (5 ml) was stirred at room temperature overnight. The mixture was diluted with water and extracted with ethyl acetate twice. The combined extracts were washed with water three times, dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography (10% methanol in dichloromethane) to give 4-{4-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]butyl}-1(2H)-phthalazinone (70 mg) as a colorless powder.

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.40 - 2.00 (4H, m), 2.30 - 3.30 (10H, m), 6.12 (1H, s), 7.00 - 7.60 (5H, m), 7.70 - 8.00 (2H, m), 8.04 (1H, d,  $J=7.6$  Hz), 8.26 (1H, d,  $J=7.6$  Hz), 12.44 (1H, brs)

Mass (ESI): 378.3 (M+H) $^+$

Example 9

The following compounds were prepared in a similar manner to that of Example 8.

- (1) 4-{4-[4-(4-Chlorophenyl)-3,6-dihydro-1(2H)-pyridyl]butyl}-1(2H)-phthalazinone  
 $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.40 - 1.90 (4H, m), 2.30 - 2.80 (8H, m), 2.95 (2H, t,  $J=7.3$  Hz), 3.06 (2H, d,  $J=2.5$  Hz), 6.20 (1H, s), 7.20 - 7.60 (5H, m), 7.70 - 8.00 (2H, m), 8.04 (1H, dd,  $J=1.5, 7.6$  Hz), 8.26 (1H, dd,  $J=1.5, 7.6$  Hz), 12.45 (1H, brs)  
Mass (ESI): 394.2 (M+H) $^+$
- (2) 4-{4-[4-(4-Methylphenyl)-3,6-dihydro-1(2H)-pyridyl]butyl}-1(2H)-phthalazinone  
 $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.40 - 1.90 (4H, m), 2.28 (3H, s), 2.30 - 3.30 (10H, m), 6.10 (1H, s), 7.13 (2H, d,  $J=8.1$  Hz), 7.31 (2H, d,  $J=8.1$  Hz), 7.70 - 8.00 (2H, m), 8.05 (1H, d,  $J=7.4$  Hz), 8.26 (1H, d,  $J=7.4$  Hz), 12.45 (1H, brs)  
Mass (ESI): 374.4 (M+H) $^+$
- (3) 4-{4-[4-(4-(Trifluoromethyl)phenyl)-3,6-dihydro-1(2H)-pyridyl]butyl}-1(2H)-phthalazinone  
 $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.40 - 2.00 (4H, m), 2.30 - 3.30 (10H, m), 6.34 (1H, s), 7.60 - 8.00 (6H, m), 8.04 (1H, d,  $J=7.7$  Hz), 8.26 (1H, d,  $J=7.7$  Hz), 12.45 (1H, brs)

WO 03/063874

PCT/JP03/00708

brs)

Mass (ESI): 428.3(M+H)<sup>+</sup>

- (4) 4-{4-[4-(4-Chlorophenyl)-1-piperazinyl]butyl}-1(2H)-phthalazinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 1.90 (4H, m), 2.20 - 3.70 (10H, m), 6.92 (2H, d, J=9.1 Hz), 7.21 (2H, d, J=9.1 Hz), 7.70 - 8.00 (2H, m), 8.04 (1H, d, J=7.4 Hz), 8.26 (1H, d, J=7.4 Hz), 12.45 (1H, brs)

Mass (ESI): 397.3 (M+H)<sup>+</sup>

- (5) 4-{4-[4-(4-Fluorophenyl)-1-piperazinyl]butyl}-1(2H)-phthalazinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 1.90 (4H, m), 2.20 - 3.30 (12H, m), 6.80 - 7.20 (4H, m), 7.70 - 8.00 (2H, m), 8.04 (1H, dd, J=1.6, 7.6 Hz), 8.26 (1H, dd, J=1.6, 7.6 Hz), 12.45 (1H, brs)

Mass (ESI): 381.3 (M+H)<sup>+</sup>

- (6) 4-{4-[4-(4-Nitrophenyl)-1-piperazinyl]butyl}-1(2H)-phthalazinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (4H, m), 2.00 - 3.70 (12H, m), 7.02 (2H, d, J=9.5 Hz), 7.70 - 8.20 (5H, m), 8.26 (1H, dd, J=1.1, 7.7 Hz), 12.45 (1H, brs)

Mass (ESI): 408.3 (M+H)<sup>+</sup>

- (7) 4-[5-(4-Phenyl-3,6-dihydro-1(2H)-pyridyl)pentyl]-1(2H)-phthalazinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.20 - 2.00 (6H, m), 2.10 - 3.20 (10H, m), 6.14 (1H, s), 7.10 - 7.60 (5H, m), 7.70 - 8.10 (3H, m), 8.26 (1H, d, J=7.4 Hz), 12.44 (1H, brs)

Mass (ESI): 374.4 (M+H)<sup>+</sup>

- (8) 4-[4-(9-Methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)butyl]-1(2H)phthalazinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.40 - 2.00 (4H, m), 2.40 - 3.20 (8H, m), 3.59 (3H, s), 3.64 (2H, s), 6.80 - 7.20 (2H, m), 7.20 - 8.40 (4H, m), 12.56 (1H, brs)

Mass (ESI): 387.3 (M+H)<sup>+</sup>Example 10

Oxalyl chloride (0.193mL, 2.21mmol) was dissolved in dichloromethane (3 mL) at -78 °C. A solution of dimethylsulfoxide (0.392 mL, 5.52 mmol) in dichloromethane (1mL) was added dropwise to that solution, and the mixture was stirred for 10 minutes at that temperature. A solution of 4-(4-hydroxybutyl)-1(2H)-isoquinolinone (60 mg, 0.276 mmol) in a mixed solvent of dichloromethane (1 mL) and dimethylsulfoxide (1 mL) was added dropwise. The mixture was stirred at -78 °C for 15minutes, and at -45 °C for 40 minutes. Triethylamine (0.70 mL) was added dropwise, and the mixture was stirred at 0 °C for 1 hour. The crude product was used for next step without purification. The crude 4-(1-oxo-1,2-dihydro-4-isoquinolinyl)butanal (59 mg) was dissolved in

WO 03/063874

PCT/JP03/00708

dichloromethane (1 mL), and 4-phenyl-1,2,3,6-tetrahydropyridine (87.9 mg, 0.552 mmol) was added. Then sodium triacetoxyborohydride (117 mg, 0.552 mmol) and acetic acid (0.032 mL, 0.552 mmol) were added to the mixture, and it was stirred at room temperature for 15 hours. Purification over silica gel chromatography gave

- 5 4-[4-(4-phenyl-3,6-dihydro-1(2H)-pyridyl)butyl]-1(2H)-isoquinolinone (24 mg, 24.2 %) as product.

$^1\text{H}$  NMR (200MHz, DMSO- $d_6$ ,  $\delta$ ): 1.59 (4H, br s), 2.4-2.7 (8H, m), 3.06 (2H, d,  $J=2.9$  Hz), 6.15 (1H, br s), 6.98 (1H, d,  $J=3.5$  Hz), 7.1-7.6 (6H, m), 7.71 (1H, t,  $J=6.7$  Hz), 7.78 (1H, d), 8.22 (1H, d,  $J=8.0$  Hz), 11.09 (1H, br s)

10

#### Example 11

- A suspension of 4-[4-(4-fluorophenyl)piperidino]butanamide (97 mg), methyl 4-oxotetrahydrothiopyran-3-carboxylate (96 mg), potassium carbonate (509 mg) in ethanol (5 ml) was stirred at 80 °C overnight. The mixture was diluted with water and extracted with dichloromethane twice. The combined extracts were dried over magnesium sulfate and concentrated. The residue was purified by preparative thin layer chromatography on silica gel (methanol/dichloromethane = 1/9) to give

- 15 2-[3-[4-(4-Fluorophenyl)piperidino]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one (55 mg) as a colorless powder.

- 20  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.00 - 3.70(21H, m), 6.90 - 7.40(4H, m), 12.64(1H, brs).  
Mass(ESI): 388.3 (M+H) $^+$

The following compounds [Example 12 to 27] were obtained according to a similar manner to that of Example 11.

25

#### Example 12

2-[3-[4-(4-Methoxyphenyl)piperidino]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

- $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.00 - 3.60(21H, m), 3.71(3H, s), 6.84(2H, d,  $J=8.7$  Hz), 7.13(2H, d,  $J=8.7$  Hz), 12.47(1H, brs).  
Mass(ESI): 400.3 (M+H) $^+$

30

#### Example 13

2-[3-[4-(4-Methylphenyl)piperidino]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

- $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.30 - 3.70(24H, m), 6.90 - 7.20(4H, m), 12.61(1H, brs).

35

WO 03/063874

PCT/JP03/00708

Mass(ESI): 384.2 (M+H)<sup>+</sup>Example 14

2-[3-[4-(4-Fluorophenyl)piperidino]propyl]-5,6,7,8-tetrahydro-4(3H)-  
5 quinazolinone  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.30 - 3.20(23H, m), 7.00 - 7.40(4H, m), 12.38(1H, brs).  
Mass(ESI): 370.3 (M+H)<sup>+</sup>

Example 15

15 2-[3-[4-(4-Chlorophenyl)piperidino]propyl]-5,6,7,8-tetrahydro-4(3H)-  
quinazolinone  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.30 - 3.20(23H, m), 7.10 - 7.60(4H, m), 12.36(1H, brs).  
Mass(ESI): 386.4 (M+H)<sup>+</sup>

Example 16

20 2-[3-[4-(4-Methylphenyl)piperidino]propyl]-5,6,7,8-tetrahydro-4(3H)-  
quinazolinone  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.20 - 3.20(26H, m), 7.00 - 7.20(4H, m), 12.34(1H, brs).  
Mass(ESI): 366.4 (M+H)<sup>+</sup>

Example 17

2-[3-[4-(4-Methoxyphenyl)piperidino]propyl]-5,6,7,8-tetrahydro-4(3H)-  
quinazolinone  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.20 - 3.20(23H, m), 3.71(3H, s), 6.83(2H, d, J=8.6 Hz),  
25 7.12(2H, d, J=8.6 Hz), 12.35(1H, brs).  
Mass(ESI): 382.3 (M+H)<sup>+</sup>

Example 18

2-[3-[4-[4-(Trifluoromethyl)phenyl]piperidine]propyl]-3,5,7,8-tetrahydro-4H-  
30 thiino[4,3-d]pyrimidin-4-one  
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ): 1.50 - 3.60(21H, m), 7.46(2H, d, J=8.2 Hz), 7.64(2H, d, J=8.2  
Hz), 12.65(1H, brs).  
Mass(ESI): 438.3 (M+H)<sup>+</sup>

Example 19

2-[3-[4-[4-(Trifluoromethyl)phenyl]piperidino]propyl]-5,6,7,8-tetrahydro-4(3H)-



WO 03/063874

PCT/JP03/00708

## quinazolinone

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ) : 1.30 - 3.20(23H, m), 7.45(2H, d, J=8.1 Hz), 7.64(2H, d, J=8.1 Hz), 12.36(1H, brs).

Mass(ESI): 420.3 (M+H)<sup>+</sup>

5

Example 20

2-[3-[(2R,6R)-4-Chlorophenyl-2,6-dimethyl-1-piperazinyl]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ) : 0.99(6H, d, J=6.0 Hz), 1.50 - 3.70(18H, m), 6.90(2H, d, J=9.0 Hz), 7.20(2H, d, J=9.0 Hz), 12.45(1H, brs).

Mass(ESI): 433.1 (M+H)<sup>+</sup>

Example 21

2-[3-[4-(4-Fluorophenyl)-3,6-dihydro-1(2H)-pyridyl]-3-methylpropyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one hydrochloride

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ) : 0.80 - 5.20(20H, m), 6.20(1H, m), 7.00 - 7.70(4H, m).

Mass(ESI): 400.1 (M+H)<sup>+</sup>

Example 22

20

2-[3-[4-[4-(Trifluoromethoxy)phenyl]-3,6-dihydro-1(2H)-pyridyl]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

<sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ) : 1.70 - 3.60(18H, m), 6.18(1H, m), 7.31(2H, d, J=8.1 Hz), 7.53(2H, d, J=8.1 Hz), 12.37(1H, brs).

25 Mass(ESI): 452.2 (M+H)<sup>+</sup>

Example 23

2-[3-[4-[4-(Trifluoromethoxy)phenyl]-3,6-dihydro-1(2H)-pyridyl]propyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone

30 <sup>1</sup>H NMR (DMSO-d<sub>6</sub>, δ) : 1.40 - 3.20(20H, m), 6.18(1H, m), 7.31(2H, d, J=8.2 Hz), 7.53(2H, d, J=8.2 Hz), 12.13(1H, brs).

Mass(ESI): 434.2 (M+H)<sup>+</sup>

Example 24

35 2-[3-[4-(4-biphenyl)pyrrolidino]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

WO 03/063874

PCT/JP03/00708

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.5-2.2(8H, m), 2.3-2.65(2H, m), 2.65-2.9(4H, m), 2.9-3.1(2H, m), 3.2-3.6(5H, m), 7.2-7.7(9H, m).

Mass: 446.4(M+H) $^+$

5 Example 25

2-[3-[4-(3,4-dichlorophenyl)-1-piperazinyl]propyl]-5,6,7,8-tetrahydro-4(3H)-quinazolinone

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.5-1.9(6H, m), 2.2-2.6(12H, m), 3.0-3.2(4H, m), 6.9(1H, dd,  $J=9.0, 2.8$  Hz), 7.09(1H, d,  $J=2.8$  Hz), 7.38(1H, d,  $J=9.0$  Hz), 12.18 (1H, br s).

10 Mass: 421.1, 423.2 (M+H) $^+$

Example 26

2-[3-[4-(3,4-dichlorophenyl)-1-piperazinyl]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

15  $^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.7-1.85(2H, m), 2.2-2.6(8H, m), 2.7-2.9(4H, m), 3.0-3.2(4H, m), 3.39(2H, s), 6.90(1H, dd,  $J=9.0, 2.5$  Hz), 7.10(1H, d,  $J=2.5$  Hz), 7.37(1H, d,  $J=9$  Hz), 12.4(1H, br s).

Mass: 441.1, 439.1(M+H) $^+$

20 Example 27

2-[3-[4-(4-biphenyl)-1,2,3,6-tetrahydropyridyl]propyl]-3,5,7,8-tetrahydro-4H-thiino[4,3-d]pyrimidin-4-one

$^1\text{H}$  NMR (DMSO- $d_6$ ,  $\delta$ ): 1.7-2.0(2H, m), 2.3-2.9(8H, m), 3.09(2H, s), 3.2-3.6(6H, m), 6.20(1H, s), 7.3-7.9(9H, m), 12.4(1H, s).


25 Mass: 444.2(M+H) $^+$

WO 03/063874

PCT/JP03/00708

## CLAIMS

1. A compound of the formula (I):



5

wherein

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

10

$-Y^1=Y^2-$  is  $\begin{array}{c} \text{---N=C---} \\ | \\ L^{11} \\ | \\ R^{21} \end{array}$ ,  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

15

[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

(1) lower alkylene,

(2) lower alkenylene,

(3) cyclo(lower)alkylene,

(4) cyclo(lower)alkenylene,

20

(5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or

(6)  $-\text{N}(\text{R}^3)-\text{L}-$  (wherein  $\text{R}^3$  is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

25

$\text{R}^{21}$ ,  $\text{R}^{22}$ ,  $\text{R}^{23}$  and  $\text{R}^{24}$  is

(1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,

30

(2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the

WO 03/063874


PCT/JP03/00708

group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or.

- (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],

provided that


- when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,



or its prodrug, or their salts.

15

2. The compound according to claim 1, wherein



20

[wherein  $X^1$  and  $X^2$  is N, O or S].

3. The compound according to claim 2, wherein


$R^1$  is hydrogen, and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is tetrahydropyridyl, piperidyl or piperazinyl, each of which is substituted with phenyl substituted with 1 or 2 substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl,

- halo(lower)alkoxy and phenyl.

4. The compound according to any one of claims 1, 2 and 3, wherein  $L^{11}$  and  $L^{13}$  is lower alkylene.


5. The compound according to any one of claims 1, 2, 3 and 4, wherein



WO 03/063874

PCT/JP03/00708

6. A pharmaceutically composition comprising a compound of the formula (I):




5 wherein

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

10



[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

15

- (1) lower alkylene,
- (2) lower alkenylene,
- (3) cyclo(lower)alkylene,
- (4) cyclo(lower)alkenylene,
- (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or
- (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

20

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

25

- (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,

30

- (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl,

WO 03/063874

PCT/JP03/00708

halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or

(3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],

provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

then  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ \diagdown \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ \diagdown \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ \diagdown \\ R^{24} \end{array}$ ,

or its prodrug, or their pharmaceutically acceptable salts, and a pharmaceutically acceptable carrier, wherein said compound is present in an amount effective for inhibiting PARP activity.

7. The pharmaceutical composition of claim 6 for treating or preventing diseases ascribed by NMDA- and NO-induced toxicity.

8. The pharmaceutical composition of claim 6 for extending the lifespan or proliferative capacity of cells or altering gene expression of senescent cells


9. The pharmaceutical composition of claim 6 for treating or preventing tissue damage resulting from cell damage or death due to necrosis or apoptosis; neural tissue damage resulting from ischemia and reperfusion injury, neurological disorders and neurodegenerative diseases; neurodegenerative diseases; head trauma; stroke; Alzheimer's disease; Parkinson's disease; epilepsy; Amyotrophic Lateral Sclerosis (ALS); Huntington's disease; schizophrenia; chronic pain; ischemia and loss following hypoxia; hypoglycemia; ischemia; trauma; nervous insult; previously ischemic heart or skeletal muscle tissue; radiosensitizing hypoxic tumor cells; tumor cells from recovering from potentially lethal damage of DNA after radiation therapy; skin aging; arteriosclerosis; osteoarthritis; osteoporosis; muscular dystrophy; degenerative diseases of skeletal muscle involving replicative senescence; age-related macular degeneration; immune senescence; AIDS; other immune senescence diseases; inflammatory bowel disorders (e.g., colitis); arthritis; diabetes; endotoxic

WO 03/063874

PCT/JP03/00708

shock; septic shock; or tumor.


10. A method of inhibiting PARP activity comprising administering a compound of the formula (I):



wherein

R<sup>1</sup> is hydrogen, halogen, lower alkyl and lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,



15 [wherein L<sup>11</sup>, L<sup>12</sup>, L<sup>13</sup> and L<sup>14</sup> is

- (1) lower alkylene,
- (2) lower alkenylene,
- (3) cyclo(lower)alkylene,
- (4) cyclo(lower)alkenylene,
- (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or
- (6)  $\text{—N(R}^3\text{)—L—}$  (wherein R<sup>3</sup> is hydrogen or lower alkyl, and L is lower alkylene or lower alkenylene), and

25 R<sup>21</sup>, R<sup>22</sup>, R<sup>23</sup> and R<sup>24</sup> is

- (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,
  - (2) carbocyclic group, which is substituted with phenyl optionally
- 30

WO 03/063874

PCT/JP03/00708

substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl or

- 5 (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],


10 provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

then  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

15 or its prodrug, or their salts.

11. A use of a compound of the formula (I):



20 Wherein

$R^1$  is hydrogen, halogen, lower alkyl or lower alkoxy,

A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring, pyridine ring, or five to seven membered partially saturated ring optionally containing one or more heteroatom(s) selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom,

25

$-Y^1=Y^2-$  is  $\begin{array}{c} \text{---N=C---} \\ | \\ L^{11} \\ | \\ R^{21} \end{array}$ ,  $\begin{array}{c} \text{---C=N---} \\ | \\ L^{12} \\ | \\ R^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ L^{13} \\ | \\ R^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ L^{14} \\ | \\ R^{24} \end{array}$ ,

[wherein  $L^{11}$ ,  $L^{12}$ ,  $L^{13}$  and  $L^{14}$  is

30

- (1) lower alkylene,
- (2) lower alkenylene,
- (3) cyclo(lower)alkylene,



WO 03/063874

PCT/JP03/00708

- (4) cyclo(lower)alkenylene,  
 (5) diradical of saturated- or unsaturated monocyclic group with one or more nitrogen atom(s), which is obtained after removal of one hydrogen atom from said monocyclic group, or  
 (6)  $-N(R^3)-L-$  (wherein  $R^3$  is hydrogen or lower alkyl, and L is lower alkylene and lower alkenylene), and

$R^{21}$ ,  $R^{22}$ ,  $R^{23}$  and  $R^{24}$  is

- (1) cyclic amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl,  
 (2) carbocyclic group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl, or  
 (3) amino group, which is substituted with phenyl optionally substituted with one or more suitable substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, lower alkyl, halo(lower)alkyl, halo(lower)alkoxy and phenyl, and which is optionally substituted with lower alkyl.],

provided that

when A and two adjacent carbon atoms of the six membered ring to be bonded with A form benzene ring,

then  $-Y^1=Y^2-$  is  $\begin{array}{c} \text{---C=N---} \\ | \\ \text{L}^{12} \\ | \\ \text{R}^{22} \end{array}$ ,  $\begin{array}{c} \text{---CH=C---} \\ | \\ \text{L}^{13} \\ | \\ \text{R}^{23} \end{array}$  or  $\begin{array}{c} \text{---C=CH---} \\ | \\ \text{L}^{14} \\ | \\ \text{R}^{24} \end{array}$ ,

or its prodrug, or their pharmaceutically acceptable salts, for manufacturing a medicament for inhibiting PARP activity.

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**